Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Animal cell

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435700100 - Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

435700200 - Involving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysate

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435700230 Tumor cell or cancer cell 258
435700240 Leukocyte (e.g., lymphocyte, granulocyte, monocyte, etc.) 118
435700250 Erythrocyte 39
435700220 Parasite or protozoa 9
Entries
DocumentTitleDate
20090221000METHODS OF QUANTIFYING TASTE OF COMPOUNDS FOR FOOD OR BEVERAGES - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R2 polypeptide and at least one T1R3 polypeptide.09-03-2009
20120202220MULTIVALENT FLUORESCENT PROBES - Multivalent fluorescent probes and methods of using these multivalent fluorescent probes for in vitro and in vivo imaging are described.08-09-2012
20090253151Self-Renewing Master Adult Pluripotent Stem Cells - The present invention relates to a method for obtaining master adult pluripotent stem (MAPS) cells from adult human corneal epithelial tissues. The MAPS cells are obtained on the basis of pluripotent markers. Further the invention provides MAPS cells that are capable of self renewal and differentiation and have characteristics similar to that of human embryonic stem cells. The MAPS cells also retain the ability to differentiate into cells of different lineages. The composition comprising MAPS cells are useful for therapeutic purposes. Further, the invention provides a culture medium for proliferation of MAPS cells.10-08-2009
20110189702PHOTOLUMINESCENT MATERIALS FOR MULTIPHOTON IMAGING - Disclosed are nano-sized materials that can exhibit luminescence in a multi-photon imaging technique. The materials include a nano-sized particle or a carbon nanotube and a passivation agent bound to the surface of the nanoparticle or nanotube. The passivation agent can be, for instance, a polymeric material. The passivation agent can also be derivatized for particular applications. For example, the luminescent materials can be derivatized to recognize and bind to a target material, for instance a biologically active material, a pollutant, or a surface receptor on a tissue or cell surface, such as in a tagging or staining protocol. The materials exhibit strong luminescence with multi-photon excitation in the near infrared.08-04-2011
20100120068G-protein-conjugated receptor having altered ligand affinity, and use thereof - A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified.05-13-2010
20090208978Panel Cell Used for Granulocyte Antibody Detection - A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody.08-20-2009
20100093001Means and methods for the production of amyloid oligomers - The present invention relates to the field of amyloid disorders, more particularly to the field of diseases where protein misfolding leads to the generation of insoluble amyloid fibers in tissues and organs. The invention provides methods for the production of soluble, toxic amyloid oligomers. The invention further provides assays using the amyloid oligomers to screen for molecules that interfere with the toxicity of the oligomers.04-15-2010
20120088252Device and Method for the Detection of Particles - The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles.04-12-2012
20120183975Taste Receptors Of The T1R Family From Domestic Dog - The present invention relates to the discovery of several genes of the domestic dog (07-19-2012
20100159484Chemotaxis diagnostic - A method is described for determining the chemotactic activity of leukocytes in a sample, in which method the expression of a cell adhesion molecule is determined.06-24-2010
20100151496ASSAYS FOR NUCLEAR HORMONE RECEPTOR BINDING - Methods and genetic constructs are provided for detecting the binding of nuclear hormone receptors to a coactivator/corepressor. The methods employ enzyme fragment complementation using fragments of β-galactosidase as the detection system. Cells are transformed to express the large fragment of β-galactosidase fused to a member of the complex with NHR for initiation of transcription and have it localized in the nucleus and to express the small fragment of β-galactosidase fused to the nuclear hormone receptor for binding to the member upon stimulation with a ligand.06-17-2010
20100151497FLUORESCENCE-BASED ASSAY FOR DETECTING COMPOUNDS FOR MODULATING THE SODIUM-CALCIUM EXCHANGER (NCX) IN "FORWARD MODE" - Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The Sodium/Calcium exchanger is an important mechanism for removing Ca06-17-2010
20110195434METHOD FOR THE ANALYSIS OF SOLID OBJECTS - A method of analysis or diagnosis of solid objects is based on real-time detection of how predefined probes interact with structures present on or in the solid object combined with the calculation of how the recorded binding curves of said probes are distributed in terms of interaction properties. The interaction properties are input to a classification algorithm which automatically determines statues of the solid object. The method is particularly advantageous for solid biological objects like tissue slices combined with antibody probes, said antibody recognizing receptors known to be over-expressed in disease states on said tissue slice.08-11-2011
20110195433Methods for Screening of Opioid Receptor Neutral Antagonists and Inverse Agonists and Uses Thereof - Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof are disclosed.08-11-2011
20090017471SOLUBLE ErbB3 METHOD OF DETECTION - The present invention discloses a method using human soluble ErbB3, for example p85-sErbB3, as a negative regulator of heregulin-stimulated ErbB2, ErbB3, and ErbB4 activation. The present invention also discloses p85-sErbB3 binding to heregulin with an affinity comparable to that of full-length ErbB3, and competitively inhibiting high affinity heregulin binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells. The present invention also uses p85-sErbB3 to inhibit heregulin-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in cells, as a negative regulator of heregulin-stimulated signal transduction, and as a block for cell growth. The present invention is also directed to nucleic acids and expression vectors encoding p85-sErbB3, host cells harboring such expression vectors, and methods of producing the protein. The present invention discloses a method of therapeutically treating human malignancies associated with heregulin-mediated cell growth such as breast and prostate cancer.01-15-2009
20100120069MULTIPOTENT/PLURIPOTENT CELLS AND METHODS - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.05-13-2010
20100112602Protein-Protein Interaction Biosensors and Methods of Use Thereof - The invention provides methods and reagents for identifying an agent, such as by screening a library of agents, that modulates the interaction of two or more polypeptides, the method comprising: introducing into a cell at least a first polypeptide, each comprising a binding domain, wherein the first polypeptide comprises a localization domain of the second polypeptide; and detecting the cellular location of the first polypeptide, the second polypeptide or a combination thereof, wherein a change in the cellular location of the first polypeptide, the second polypeptide or a combination thereof indicates that the agent modulates the interaction of the two or more polypeptides. The invention also provides methods and reagents for identifying the binding domains of one or more polypeptides.05-06-2010
20100112601NOVEL MONOCLONAL ANTIBODY AND USE OF THE SAME - The present invention provides an anti-PAC1 monoclonal antibody capable of recognizing a PAC1 having a native structure, a PAC1 activity regulator (in particular, activity inhibitor) containing the antibody, a prophylactic/therapeutic agent for a disease associated with accentuation of a bioactivity of PAC1, containing the antibody, a diagnostic reagent for a disease associated with an abnormality of PAC1 activity, containing the antibody, and a screening method for a substance that regulates the expression of PAC1, using the antibody and a PAC1-expressing cell.05-06-2010
20100075343NOVEL PEPTIDES - The present invention provides novel peptides with energy-modulating activity or circulatory function-modulating activity. The peptides of the present invention have energy-modulating activity or circulatory function-modulating activity and thus are useful for treating food consumption disorders and diseases of the circulatory system.03-25-2010
20080213803ASSESSMENT OF NEURONS IN THE ARCUATE NUCLEUS TO SCREEN FOR AGENTS THAT MODIFY FEEDING BEHAVIOR - Screening methods of use in identifying agents that affect caloric intake, food intake, appetite, and energy expenditure are disclosed herein. These methods are used to identify agents of use in treating obesity, or that can be used to decrease the weight of a subject. These methods can also be used to identify agents of use in treating anorexia or cachexia and can be used to increase appetite and to increase the weight and lean body mass of a subject.09-04-2008
20130078649COMBINATION THERAPY FOR THE TREATMENT OF OBESITY AND DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.03-28-2013
20130078648DIRECT EXAMINATION OF BIOLOGICAL MATERIAL EX VIVO - The present invention relates to a method for the visual examination of biological material ex vivo and an apparatus for the sterical orientation of biological material which can be used in said method.03-28-2013
20130078646ANTIBODIES, COMPOSITIONS, AND ASSAYS FOR DETECTION OF CARDIAC DISEASE - The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF.03-28-2013
20130078647Methods of Detection of Changes in Cells - Methods are provided to detect changes in cells without the use of detection labels.03-28-2013
20090123943Characterization and Identification of Unique Human Adiponectin Isoforms and Antibodies - The invention pertains to methods for measuring different forms of human adiponectin that are present in human plasma/serum, and more specifically methods are based on an ELISA assay that utilizes different monoclonal antibodies directed against adiponectin, in combination with different polyclonal antibodies directed against different domains of human adiponectin. The invention also provides unique isoforms of adiponectin and antibodies thereto, including polyclonal and monoclonal antibodies.05-14-2009
20130040317CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators.02-14-2013
20130040318INCREASE OF MYELOID MICROVESICLES IN THE CEREBROSPINAL FLUID AS BIOMARKER OF MICROGLIA/MACROPHAGE ACTIVATION IN NEUROLOGICAL DISORDERS - The present invention relates to a method for the diagnostic and/or prognostic of a neurological disease characterized by an inflammation process in a subject comprising measuring the amount of myeloid derived microvesicles in a cerebrospinal fluid sample obtained from the subject. The invention further relates to a method for predicting and/or monitoring the efficacy of a treatment for a neurological pathology or for monitoring a neurological disease progression.02-14-2013
20130040315HUMAN AND MURINE STEM-CELL LINES: MODELS OF ENDOTHELIAL CELL PRECURSORS - The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same, In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and/or veterinary fields, in particular in the field of therapeutics and/or in the field of studies of cellular mechanisms.02-14-2013
20130040316CELL LINES COMPRISING ENDOGENOUS TASTE RECEPTORS AND THEIR USES - Provided herein are cell lines and assays that can be utilized to identify taste receptor modulators.02-14-2013
20090176254MAMMALIAN GALANIN RECEPTORS - The present invention provides isolated mammalian GalR3 receptors, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the receptors using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptors and are useful for treating medical conditions caused or mediated by galanin. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian GalR3 receptors.07-09-2009
20100099121METHOD FOR THE DIAGNOSIS OF CANCERS BY MEASURING THE CHANGES OF GLYCOSYLATION OF PROTEINS RELATED TO TUMORIGENESIS AND METASTASIS AND KIT FOR DIAGNOSIS OF CANCERS USING THE SAME - The present invention relates to a method for diagnosing cancers by measuring proteins associated with tumorigenesis and metastasis, and a diagnostic kit using the same, particularly relates to the method for diagnosing cancers by measuring the changes of glycosylation of proteins and the kit for diagnosis of cancers using the said method. The method and kit of the present invention can effectively be used for the sensitive diagnosis of cancers comprising colon cancer, stomach cancer, lung cancer and liver cancer.04-22-2010
20080311593METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods.12-18-2008
20130045489NEURAL NANOPROBES - Neural nanoprobes are described, as well as methods for their use, including for use as a tagging system for neuronal pathway identification. The neural nanoprobes comprise metallic nanoparticles that are conjugated to both (i) a cationic polymer such as polyethylenimine and (ii) an antibody to a vesicular transporter protein. These methods allow retrograde characterization of glutamatergic neurons in a tissue slice preparation. Since the nanoparticles used are non-lipid-soluble and are specifically conjugated to enter and escape the synaptic vesicular machinery, these nanoparticles allow probing of a neuron's somatic origin, via the synapse, by diffusional means.02-21-2013
20090155819Mammalian T1R3 Sweet Taste Receptors - The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors, the receptors comprising consisting of a monomer or homodimer of a T1R3 G-protein coupled receptor polypeptide, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.06-18-2009
20090155818Measuring Receptor Homodimerization - The invention provides methods and kits for detecting and/or measuring receptor homodimers on a cell surface membrane. In one aspect, the methods employ pairs of probes comprising binding compounds and a cleaving probe, such that at least one binding compound binds specifically to the same epitope of a membrane-bound analyte as the cleaving probe. The binding compound includes one or more molecular tags attached through a cleavable linkage, and the cleaving probe includes a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to a homodimer of a cell surface molecules results in release of molecular tags from the binding compounds, providing a measure of formation of the homodimeric complex.06-18-2009
20100105080Methods For Determining The Bioactivity Of TGF-Beta In A Composition - A novel method for determining the bioactivity of TGF-β in a sample of milk, raw protein source, or nutritional composition is provided. The method includes particular reconstitution steps, centrifugation steps, incubation steps, and activation steps. The bioactivity of the TGF-β in the sample may be measured in a HT-2 cell bioassay or a cellomics bioassay.04-29-2010
20100041072PROCESS FOR IDENTIFYING A LIGAND THAT BINDS TO THE NEP BINDING SITE FOR THE SMR1 PENTAPEPTIDE - The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.02-18-2010
20100068731Use of N-Myristoyltransferase on Non-Tumor Tissue for Cancer Diagnosis - A diagnostic method and kit are disclosed for detection of cancer. Detection of elevated levels of N-myristoyltransferase (NMT) or NMT activity in blood or bone marrow, and specifically in peripheral blood mononuclear cells, can be used as a marker for cancer. The use of this method for detection of adenocarcinoma, such as colorectal cancer, is exemplified.03-18-2010
20090123946IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.05-14-2009
20090123944Bioassays - The invention relates to vectors encoding bioassay receptors and in vitro bioassays using said bioassay receptors for assessing compounds of interest. In particular, the bioassays provide a generic platform for the comparison of binding of different ligands to their respective receptors or binding partners in the presence and/or absence of a compound of interest.05-14-2009
20090123942Electrophysiological assays using oocytes that express human enac and the use of phenamil to improve the effect of enac enhancers in assays using membrane potential reporting dyes - In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.05-14-2009
20130052663Chimeric Receptors and Methods for Identifying Agents Exhibiting an Activity on Type 1 Single Pass Transmembrane Receptors - The present invention provides novel chimeric receptors and methods of screening using the chimeric receptors. The chimeric receptors comprise an extracellular domain of a type 1 single pass transmembrane receptor (T1SPTR) and an intracellular domain with kinase activity stemming from a receptor tyrosine kinase. According to an embodiment, the chimeric receptor comprises a full-length T1SPTR. According to another embodiment the chimeric receptor comprises a full-length or truncated tumor necrosis factor receptor (TNFR) or interleukin receptors, or cytokine receptors, or transforming growth factor receptors. The present invention provides means for screening of modulators of TNFRs or interleukin receptors, or cytokine receptors, or transforming growth factor receptors.02-28-2013
20130052662Method for Automated Autoantibody Detection and Identification - The present invention is a kit and method for detecting and identifying autoantibodies. The invention employs the use of indirect immunofluorescence, imaging flow cytometry and pattern recognition software to automatically identify autoantibodies associated with autoimmune disorders.02-28-2013
20130052661Methods for Biomolecule and Biomolecule Complex (BMC) Detection and Analysis and the Use of Such for Research and Medical Diagnosis - The present application pertains to improved methods of detecting biomolecules in a biological sample (or system), In particular, embodiments discussed herein allow for the detection of biomolecule complexes. The embodiments enable for the first time the elucidation of the significance of biomolecule complexes for certain disease states, which in turn enables the diagnosis of disease states based on the identity and complexing level of a biomolecule complex in a particular biological sample.02-28-2013
20100003703ASSAY SYSTEM FOR GLP-2 RECEPTOR LIGANDS - Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue.01-07-2010
20090042220Method for monitoring collagen type II degradation in cartilage - A method for improving the diagnostic assessment of cartilage degenerative processes, and to provide means of monitoring the effects of therapeutical measures taken towards arthritic diseases in most mammals utilizes an immunoassay to detect fragments of collagen type II resulting from collagenase activity comprising an antibody directed against an epitope comprised in the amino acid sequence HRGYPGLDG (SEQ ID NO:1), located in the helical region of collagen type II.02-12-2009
20090042219Novel Transporter Protein in Mammal and Utilization of the Same - The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.02-12-2009
20110003320IMMUNOASSAY METHOD AND KIT AND DEVELOPING SOLVENT THEREFOR - An immunoassay method and a kit which comprises a combination of a test piece for immunochromatography and a developing solvent, by which a target substance is detected accurately in a short period of time while a preventing a nonspecific reaction.01-06-2011
20090305310Methods for Determining Notch Signaling and Uses Thereof - The invention relates, in part, to methods of determining Notch signaling in cells, tissues and/or subjects. The invention additionally relates, in part, to diagnostic assays for cell differentiation-associated diseases or conditions and for screening tools in research and clinical applications.12-10-2009
20090305309Methods and Compositions for Detecting Neoplastic Cells - Methods and compositions for identifying neoplastic cells in a biological sample are provided.12-10-2009
20090305308METHOD FOR IDENTIFYING CELL-SPECIFIC PROTEIN COMBINATION PATTERNS - The present invention discloses a method for identifying cell-specific protein combination patterns of cell surfaces of circulating cells of the immune system of a human or animal for the identification of different stages of organ-specific chronic inflammatory diseases or tumour diseases comprising the following steps: a) providing a sample of circulating cells of the immune system of a human or animal showing an organ-specific chronic inflammatory disease or tumour disease and providing a sample of circulating cells of the same cell type of the immune system of a healthy human or animal; b) determining cell-specific protein combination patterns of the cell surfaces of said healthy and pathologically modified cells; c) comparing the resulting protein combination patterns of the cell surfaces of said healthy and pathologically modified cells and subtracting the coincident parts of the protein combination patterns of said healthy and pathologically modified cells, thereby determining a cell-specific protein combination patterns of the cell surfaces of said pathologically modified cells resulting therefrom; and d) identifying and characterizing the resulting cell-specific protein combination pattern of the cell surfaces of said pathologically modified circulating cells of the immune system in terms of molecules and its spatial arrangement within the cell as disease specific. The invention moreover relates to compositions and kits comprising antibodies and/or ligands which can be employed for the performance of the method.12-10-2009
20130071858AUTOMATED STAINING SYSTEM AND REACTION CHAMBER - An apparatus including a reagent cartridge and a reaction chamber, the reagent cartridge having a reagent capsule removably positioned therein for dispensing of a reagent onto the reaction chamber. A system including a linearly translatable mounting assembly having a plurality of mounting stations dimensioned to receive at least one fluid dispensing cartridge, a linearly translatable bulk reagent dispensing assembly having a plurality of bulk reagent dispensing nozzles coupled thereto and a receiving assembly positioned beneath the mounting assembly and the bulk reagent dispensing assembly, the receiving assembly including a plurality of reaction stations. A method including determining an inventory of an automated sample processing system, downloading a processing protocol from a central controller to the automated sample processing system, operating the automated sample processing system based on the processing protocol and independently of the central controller and dispensing a reagent from the automated sample processing system.03-21-2013
20090093002HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.04-09-2009
20130059317Binding Partners for the Thyrotropin Receptor and Uses Thereof - A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.03-07-2013
20110059468Magnetic separation device for cell sorting and analysis - A magnetic sifter is adapted for manipulation of biological cells by providing a greater pore density at the edge of the sifter than at the center. Application of an external magnetic field to the sifter causes high magnetic fields and field gradients at the sifter pores. These conditions are suitable for capturing magnetically tagged or labeled cells at the sifter pores. Altering the external magnetic field can provide controlled capture and/or release of magnetically labeled cells from the sifter pores. The purpose of having a greater pore density at the periphery of the sifter than at the center is to provide improved flow rate uniformity through the sifter. Such flow rate uniformity is advantageous for cell quantification.03-10-2011
20110014635MARKER PEPTIDE FOR ALZHEIMER'S DISEASE - To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein α, Alcadein β, or Alcadein γ; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker.01-20-2011
20110014634NUCLEIC ACIDS ENCODING T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides isolated nucleic acid and amino acid sequences of taste cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste cell specific G-protein coupled receptors.01-20-2011
20090269786RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies - This invention provides antibodies immunologically specific for ρ1-GABA10-29-2009
20130065253DETECTION SYSTEM AND USES THEREFOR - A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group; iv) a modulator; and v) a detector; wherein proximity of the first and second reporter components generates a signal capable of detection by the detector; and wherein the modulator modulates the association of the second interacting group with the third interacting group; such that monitoring the signal generated by proximity of the first and second reporter components by the detector constitutes monitoring the association of the first and third agents.03-14-2013
20130065252COMPOSITIONS AND METHODS FOR DETECTING AUTOANTIBODIES - The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are associated with the presence of TBI and/or TSI, for monitoring the progress of disease and/or treatment regimens, therapeutics, vaccines, etc., and for assisting clinicians in making treatment decisions.03-14-2013
20110020841CENTROSOME AMPLIFICATION AS A BIOSENSOR FOR DNA DAMAGE - The present invention provides an assay kit for identifying and/or monitoring genotoxic modulating agents comprising eukaryotic cells, characterised in that the cells stably express at least one labelled centrosome marker.01-27-2011
20090239246Biomarkers - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.09-24-2009
20090258376Protein isoforms and uses thereof - There is provided a method for screening for or, diagnosis or prognosis of a neurological disorder in a subject, for determining the stage or severity of such a neurological disorder in a subject, for identifying a subject at risk of developing such a neurological disorder, or for monitoring the effect of therapy administered to a subject having such a neurological disorder, said method comprising: 10-15-2009
20090215085Proteomic Fingerprinting of Human IVF-Derived Embryos: Identification of Biomarkers of Developmental Potential - The present invention discloses biomarkers and biomarker combinations that have prognostic value as predictors of the developmental potential of individual IVF-derived human embryos. In particular, the biomarkers of this invention are useful to classify an embryo with implantation competence after uterine transfer or implantation incompetence. In addition, the biomarkers can be detected by non-invasive methods that do not harm the developing embryo. Also disclosed are kits for the prediction of developmental potential that detect the biomarkers of the invention, as well as methods using a plurality of classifiers to make a probable diagnosis of developmental potential.08-27-2009
20100028911MULTICOLOR REAGENTS CONTAINING COMPENSATION CONTROLS - The present invention provides multicolor reagent formulations containing in a single container both fluorescently labeled detection reagents and single-color compensation control reagents, wherein the compensation control reagents consist of reagent-capture particles bound to a fluorescently labeled detection reagent included in the multicolor reagent formulation. The multicolor reagent formulations of the present invention simplify manufacture and commercial distribution of multicolor reagent kits.02-04-2010
20100086948Ovarian Cancer Biomarkers and Uses Thereof - The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.04-08-2010
20120237951ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A - A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W—[X09-20-2012
20100330590ASSAYS USING CHIMERIC T1R3 TASTE RECEPTOR POLYPEPTIDES - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.12-30-2010
20090111126MAMMALIAN CELL-BASED IMMUNOGLOBULIN DISPLAY LIBRARIES - Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.04-30-2009
20110281282SUBPOPULATIONS OF SPORE-LIKE CELLS AND USES THEREOF - Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.11-17-2011
20110129854ASSAY FOR DIAGNOSIS OF CARDIAC MYOCYTE DAMAGE - Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result.06-02-2011
20090220998Platelet Aggregation Assays - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.09-03-2009
20090233317REPRESSOR OF SKELETAL MUSCLE DIFFERENTIATION, NUCLEIC ACIDS CODING THEREFOR AND THE USE THEREOF IN DIAGNOSIS AND THERAPY - Polypeptide sequences which play a part in the regulation of skeletal muscle differentiation, and nucleic acids coding therefor, and the use thereof in diagnosis and therapy are disclosed. Possible uses are also indicated for antibodies which are directed against corresponding epitopes of the GRIM1 polypeptide.09-17-2009
20110053183METHOD OF CONCENTRATING HUMAN MESENCHYMAL STEM CELLS - The present invention is intended to provide methods for highly enriching human mesenchymal stem cells from a cell population containing the human mesenchymal stem cells. To highly enrich human mesenchymal stem cells, CD27103-03-2011
20130022994REGULATION OF BACE DEGRADATION - The invention relates to methods and products for diagnosing, preventing, and treating Alzheimer's disease and abnormal production of amyloid β.01-24-2013
20110281281INTEGRATION-FREE HUMAN INDUCED PLURIPOTENT STEM CELLS FROM BLOOD - Provided herein are methods for generating human induced pluripotent stem cells free from genomic integration of exogenous transgenes by transfecting into nucleated blood cells one or more DNA expression vectors (e.g., plasmid vectors) that do not contain a mammalian origin of replication, and encode and permit expression of one or more reprogramming factors (e.g., Oct4, Sox2, Klf4, and c-Myc). Also provided herein are the integration-free human induced pluripotent stem cells obtained by the methods described herein.11-17-2011
20110300560NOVEL MEMBERS OF THE CAPSAICIN/VANILLOID RECEPTOR FAMILY OF PROTEINS AND USES THEREOF - The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.12-08-2011
20110300559COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER AND NEURODEGENERATIVE DISEASES RELATED TO BECLIN-1 - The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a phospho-mimicking residue and uses thereof for treating cancer and neurodegenerative diseases.12-08-2011
20110143376Methods to Identify Modulators - TAS2R7 was identified as a menthol-binding bitter taste receptor. Novel methods to identify modulators and in particular inhibitors to the bitter taste of menthol are provided.06-16-2011
20110143373METHOD OF EVALUATING THE INTEGRITY OF THE PLASMA MEMBRANE OF CELLS BY DETECTING GLYCANS FOUND ONLY INTRACELLULARLY - The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.06-16-2011
20110171663MICROTRENCH AND TUMOUR PROLIFERATION ASSAY - There is provided a cell culture microtrench being defined on or in a surface of a substrate, wherein the ratio of the width of the microtrench to the maximum length of the short axis of a cell type of interest is about 6 or preferably less, the length of the short axis of the cell type being measured when a cell is in detached or suspended form. There is also provided an array comprising such a microtrench and uses of such microtrenches, including cell-based assays.07-14-2011
20090275056Methods for obtaining antibodies - The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.11-05-2009
20090298096Interleukin-1 alpha ABS and methods of use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.12-03-2009
20090280509SURFACE ACOUSTIC WAVE IMMUNOSENSOR FOR DIAGNOSING ALLERGY DISEASE AND METHOD FOR DIAGNOSING ALLERGY DISEASE USING THE SAME - A surface acoustic wave (SAW) immunosensor for diagnosing allergy disease includes one or more SAW devices on each of which allergens derived from one allergy-causing substance are fixed and an allergen derived from another allergy-causing substance is not included, that is, allergens derived from different allergy-causing substances being fixed on different SAW devices; and a signal detector which detects an output signal from the SAW device. Also a method for diagnosing allergy disease is capable of measuring levels of allergen-specific IgE and total IgE in blood or another sample taken from a subject of diagnosis using a SAW immunosensor, the allergens being derived from various allergy-causing substances, thereby capable of effectively diagnosing allergy disease for various allergy-causing substances.11-12-2009
20090253153METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY - The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.10-08-2009
20090123945CHOLINERGIC/SEROTONINERGIC RECEPTOR AND USES THEREOF - The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors.05-14-2009
20090098580MAMMALIAN SWEET TASTE RECEPTORS - The present invention provides isolated nucleic acid and amino acid sequences of sweet taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet taste receptors.04-16-2009
20090098579HUMAN T1R2 POLYPEPTIDE FUNCTIONAL ASSAYS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.04-16-2009
20090317832Cell Classification System - The present invention involves the reaction of a CD4 immuno-conjugate with a sample of patient whole blood. The CD4 immuno-conjugate consists of one or more antibodies with specificity for the CD4 surface receptor coupled to a signal moiety, or “label”, that is detectable by a flow cytometer. Such labels may generate a signal by such means as fluorescence properties, light scatter properties, electronic properties, or magnetic properties. The CD4 immuno-conjugate binds to both the CD4 positive lymphocytes (Helper T cells) and all monocytes. Differential detection means are employed to count immuno-conjugate labeled Helper T cells. The present invention distinguishes itself by simultaneously measuring the signal level from monocytes as a means to verify sufficient activity of the anti-CD4 antibody.12-24-2009
20100112600Methods and compositions for modulating synapse formation - The invention provides methods of modulating synapse formation. Methods for identifying agents to modulate synapse formation are also disclosed.05-06-2010
20100112603METHOD FOR PREDICTING THE RESPONSE TO A TREATMENT - The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.05-06-2010
20100267057Cell Surface Display, Screening and Production of Proteins of Interest - Aspects of the invention provide compositions and methods for displaying engineered polypeptides on a cell surface. According to aspects of the invention, immobilized polypeptides can be screened to identify one or more variants having one or more functional or structural properties of interest. Aspects of the invention provide composition and methods for producing engineered protein or protein variants having a functional or a structural property of interest.10-21-2010
20100055718NANOPLATE DYE PLATFORM AND METHODS OF MAKING AND USING THE SAME - Embodiments disclosed herein relate to labeling reagents comprising a plurality of nanoplates attached to dye molecules. The nanoplates may be configured into stacks and/or at least partially surrounded by a surrounding layer. The reagent may then be used to label a target (e.g., structure or environment).03-04-2010
20080268471USE OF SPECIFIC T2R RECEPTORS TO IDENTIFY COMPOUNDS THAT BLOCK BITTER TASTE - Assays for identifying compounds that modulate, preferably inhibit bitter taste associated with the activation of hT2R4, hT2R44 and/or hT2R61 are provided. The compounds identified according to these assays should modulate, e.g., inhibit bitter taste associated with bitter tasting compounds including quinine, 6-nitrosaccharin, saccharin and/or denatonium. These compounds are useful additives for foods, beverages or medicinal preparationshaving a bitter taste.10-30-2008
20100279317Method - The present invention provides a method for identifying a single or group of T cell receptors (TCR) protective and/or effective against a disease, having the following steps: i) obtaining T cells from a donor non-human animal; ii) adoptive transfer of the T cells into a plurality of T cell-deficient recipient non-human animals in a number such that at least one recipient animal is protected against the disease but at least one animal remains unprotected; and iii) determination of the TCR(s) present only in the protected animals. These TCR can be used to identify the determinants or antigens for inclusion in a vaccine or other treatment.11-04-2010
20110207149METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.08-25-2011
20100015639Methods and Kits to Detect and Monitor Ovarian Cancer and Preeclampsia - The present invention provides methods and kits related to a prognostic, and, in certain embodiments, diagnostic indicator for ovarian cancer which comprises measuring the level of MUC16 bound to immune cells. The level of MUC16 bound to immune cells can by itself be an indicator of disease regression or recurrence, or this indicator can be used in conjunction with assays for serum CA125 and other diagnostic markers. The invention further provides methods and kits related to the detection of ovarian cancer by measuring levels of Siglec-9 expression on immune cells. As well, related methodologies are provided for the detection of preeclampsia in pregnant human subjects.01-21-2010
20100086946PLGF, FLT1 AND ENDOGLIN FOR DIAGNOSING ANGIOGENIC STATUS IN CORONARY ARTERY DISEASE - Described are methods for diagnosing the angiogenic status of a subject suffering from coronary heart disease comprising determining the amounts of placental growth factor or a variant thereof, endoglin or a variant thereof and soluble FLT1 or a variant thereof in a sample of a subject suffering from coronary heart disease and comparing the amounts determined with reference amounts, whereby the angiogenic status is diagnosed. Also disclosed are diagnostic devices and kits for carrying out the aforementioned methods04-08-2010
20100086947USE OF FLOW-CYTROMETRIC ANALYSIS TO OPTIMIZE CELL BANKING STRATEGIES FOR CHO CELLS - Production of biopharmaceuticals from CHO cells requires generation of master-, working- and post-production cell banks of high quality, partly under GMP conditions. An optimal cryopreservation strategy is needed for each new production cell line, particularly with regard to the desire to establish production processes that are completely devoid of serum or even any animal components and to ensure robust thaw performance for reliable production. Here we describe a novel strategy employing flow cytometric (FC) analysis of Annexin V-stained cells for high-throughput characterization of CHO cell banks. Our data show that this method enables evaluation of a cryopreservation procedure just 6 h after thaw.04-08-2010
20120034625Monoclonal Antibody Capable of Binding Integrin Alpha 10 Beta 1 - The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen and Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 produced by the hybridoma cell line deposited. Methods and uses of said antibody or a fragment thereof in identifying and selecting cells of a chondrogenic nature for treatment purposes, in particular for the identification and isolation of chondrocytes, mesenchymal progenitor cells and embryonic stem cells for tissue engineering of cartilage, or for identifying diagnostic and therapeutic tools in studying the biological role and the structural/functional relationships of the integrin alpha10beta1 with its various extracellular matrix ligands are also included.02-09-2012
20110201029IL-13 RECEPTOR ANTIBODIES - This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and uses thereof.08-18-2011
20100081149NOVEL OXIDIZED LDL COMPLEX AND METHOD FOR DETECTION THEREOF - Serum amyloid P component, oxidized LDL and β2-glycoprotein I can together form a complex. The presence of a disease such as hyperlipemia and atherosclerosis can be determined by detecting the complex by using either one of an anti-serum amyloid P component antibody and an anti-β2-glycoprotein I antibody.04-01-2010
20090263835Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells - Genes that are up- or down-regulated during differentiation provide important leverage by which to characterize and manipulate early-stage pluripotent stem cells. Over 35,000 unique transcripts have been amplified and sequenced from undifferentiated human embryonic stem cells, and three types of differentiated progeny. Statistical analysis of the assembled transcripts identified genes that alter expression levels as differentiation proceeds. The expression profile provides a marker system that has been used to identify particular culture components for maintaining the undifferentiated phenotype. The gene products can also be used to promote differentiation; to assess other relatively undifferentiated cells (such as cancer cells); to control gene expression; or to separate cells having desirable characteristics. Manipulation of particular genes can be used to forestall or focus the differentiation process, en route to producing a specialized homogenous cell population suitable for human therapy.10-22-2009
20120270236VOLTAGE-GATED PROTON CHANNEL, Hv1, AND USES THEREFOR - Nucleic acid and protein sequences relating to a proton channel (HvI) are disclosed. Nucleic acids, vectors, transformed cells, transgenic animals, polypeptides, and antibodies relating to the HvI gene and protein are disclosed. Also provided are methods of identifying modulators of HvI activity, methods of geno typing subjects with respect to HvI, and methods of diagnosing and treating HvI-mediated disorders.10-25-2012
20090162873GENE ENCODING A MULTIDRUG-RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell s susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance.06-25-2009
20090280510Antibodies Specific to Heterodimers of Bcl-2 Family and Uses Thereof - Isolated antibodies specifically binding to heterodimers of the Bcl-2 family and uses thereof for detecting presence of Bcl-2 heterodimers in a patient.11-12-2009
20110201030Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.08-18-2011
20110201027BIOSENSOR FOR DETECTING A TRACE AMOUNT OF SAMPLE AND PRODUCTION METHOD THEREFOR - The present invention relates to a biosensor capable of a trace amount of sample and a fabrication method thereof. More specifically, the invention relates to a method for fabricating a biosensor, the method comprising: immobilizing a receptor molecule, which binds selectively to a target substance, on an electrically insulated nano-electrode chip; binding an enzyme to the receptor molecule; and treating the bound enzyme with metal ions and depositing the metal ions on the nano-electrode surface, and to a biosensor fabricated thereby. According to the invention, a precipitate is produced on the nano-electrode surface by a precipitation between the enzyme and the metal ions, and the produced precipitate electrically connects the nano-electrodes together, thereby increasing electrical conductivity. Thus, the invention is useful for quantitative analysis of trace amounts and/or various concentrations of target substances.08-18-2011
20110201028T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners.08-18-2011
20090170129DETECTION OF CIRCULATING ENDOTHELIAL CELLS - Endothelial cells are detected in a blood sample by enriching the endothelial cells from the blood sample followed by performing on the enriched endothelial cells an immunoassay capable of detecting antigens expressed by the endothelial cells. The immunoassay is capable of detecting antigen expressed from 300 endothelial cells per milliliter of blood. The method can be used for assaying mature circulating endothelial cells or circulating endothelial progenitor cells.07-02-2009
20090286263SKIN TAPE STRIPPING: A NON-INVASIVE DIAGNOSTIC STRATEGY FOR DERMAL EXPOSURE TO CYTOTOXIC COMPOUNDS - A non-invasive method for determining a subject's dermal exposure to an agent employing an immunohistochemical procedure on a skin strip applied to an exposed area on the subject's person and detecting agent adduct thereon.11-19-2009
20130189711METHODS, PRODUCTS AND TREATMENTS FOR DIABETES - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.07-25-2013
20090286262NUCLEIC ACID, POLYPEPTIDE AND ITS USE - Novel chimeric proteins functional to screen for sweet taste modulators, the corresponding nucleic acid sequences, expression vectors, transfected host cells, and screening methods for modulators and enhancers of the sweet taste response employing the aforementioned are provided.11-19-2009
20090286264IMAGING OF IMMUNOMAGNETICALLY ENRICHED RARE CELLS - A method for removing excess unbound ferrofluid and imaging immunomagnetically enriched circulating tumor cells is provided. A vessels having a preformed grooves in the viewing surface is optimally designed for cell alignment and imaging. After separating the unbound particles by centrifugation, an externally-applied force is applied to transport magnetically responsive particle-CTC complex toward the transparent collection wall. The grooved inner surface of the viewing face of the chamber provide uniform distribution of the particles for easy imaging. The invention is also useful in conducting quantitative analysis and sample preparation in conjunction with automated cell enumeration techniques as in quantitative analysis of CTC in disease.11-19-2009
20090093003PORCINE UMAMI TASTE RECEPTORS AND USES THEREFOR - The present invention provides nucleic acids encoding porcine taste receptors, polypeptides encoded by the nucleic acids, and methods of using the nucleic acids and polypeptides to identify compounds that enhance umami taste.04-09-2009
20100279318METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise. The method uses a transmembrane protein that comprises a nuclear localization sequence (NLS)11-04-2010
20100136582METHOD FOR IDENTIFICATION OF SOMATIC STEM CELLS - The invention relates to a method for identification of somatic stem cells, wherein the spatial arrangement of epitopes in a sample is captured by MELC technology for identifying the phenotype specific to the somatic stem cells. The invention moreover relates to a composition, a kit and a biochip comprising at least one antibody and/or ligand which can be employed for the performance of the method.06-03-2010
20100143944Systems and methods for rapidly changing the solution environment around sensors - The invention provides microfluidic systems for altering the solution environment around a nanoscopic or microscopic object, such as a sensor, and methods for using the same. The invention can be applied in any sensor technology in which the sensing element needs to be exposed rapidly, sequentially, and controllably, to a large number of different solution environments whose characteristics may be known or unknown.06-10-2010
20080274480Botulinum Toxin Type a Immunoresistant Assay - The present specification discloses methods for determining Botulinum Toxin Type A immunoresistance in a mammal by detecting the amount of BoNT/A toxin-BoNT/A receptor complexes or the amount of free BoNT/A present or absent in a sample.11-06-2008
20080286813Antibody specific for mutant presenilin 1 and method of use thereof - The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.11-20-2008
20110269153Immunoassay Device with Improved Sample Closure - An apparatus and method for sealing a fluid sample collection device, comprising: loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.11-03-2011
20080305501Compositions and Methods for Modulating Rank Activities - The present invention provides methods for identifying agents capable of modulating RANK-mediated invention also provides pharmaceutical compositions and methods of using the same for treating osteoporosis or other diseases. The present invention is based on the functional and structural analysis of a novel RANK signaling motif that was found to play a distinct role in activating RANK-mediated intracellular signaling. This motif can be used to screen for RANK modulators. This motif for treating a variety of diseases that are caused by or associated with abnormal RANK expression or activities.12-11-2008
20090317834NOVEL CELLULAR GLYCAN COMPOSITIONS - The invention describes novel compositions of glycans, glycomes, from human embryonic stem cells, and especially novel subcompositions of the glycomes with specific monosaccharide compositions and glycan structures. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore, the invention is directed to stem cells carrying the modified glycomes on their surfaces. The glycomes are preferably analysed by profiling methods able to detect reproducibly and quantitatively numerous individual glycan structures at the same time. The most preferred type of the profile is a mass spectrometric profile. The invention specifically revealed novel target structures and is especially directed to the development of reagents recognizing the structures.12-24-2009
20100143943DETECTION OF DYSPLASTIC OR NEOPLASTIC CELLS USING ANTI-MCM2 ANTIBODIES - Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.06-10-2010
20110269152Anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell - An anchoring/capturing system for selecting or analyzing a CHO cell according to a product secreted by the CHO cell is described. The anchoring/capturing system comprises a first antibody or a first antigen-binding fragment for anchoring to the extracellular surface of the CHO cell, and a second antibody or a second antigen-binding fragment for binding the secreted product. Uses and methods involving the anchoring/capturing system are provided.11-03-2011
20110207147Compositions and Methods for Modification of Biomolecules - Provided are modified cycloalkyne compounds; and methods of use of such compounds in modifying biomolecules. Embodiments include a cycloaddition reaction that can be carried out under physiological conditions. The cycloaddition reaction involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo and in vitro.08-25-2011
20110207148T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners.08-25-2011
20090136970NOGO RECEPTOR HOMOLOGUES AND THEIR USE - This invention relates to gene polypeptides and polynucleotides that encode proteins of the Nogo-66 receptor (NgR) family and are therefore called NgR homologue 1 (NgRH1). The invention further relates to their use in identifying compounds that may be agonists or antagonists that are potentially useful in regeneration and protection of the nervous system, and to production of NgRH1 polypepfldes, derivatives, and antibodies.05-28-2009
20090004676T1R3 receptor binding assays for identification of taste modulatory compounds - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically. T01-01-2009
20080318250Compositions and Methods for Identifying Sperm for Forensic Applications - Methods and compositions for identifying and isolating sperm cells from samples containing multiple cell types are described. The methods and compositions employ antibodies that specifically bind to sperm-specific antigens located on or internal to the sperm plasma membrane. A reporter molecule may be conjugated to the antibodies to aid in the detection of sperm. The antibodies may be targeted to sperm-specific antigens in the head and/or tail of sperm to facilitate the identification and isolation of sperm cells from forensic samples prepared from sexual assault evidence. Purified DNA from the isolated sperm cells can be amplified by polymerase chain reaction to assist forensic analysis in sexual assault cases.12-25-2008
20090325197ASSAY FOR IMMUNOSUPPRESSANT DRUGS - The invention provides immunoassays for immunosuppressant drugs, wherein the assay is carried out under high salt conditions to achieve improved sensitivity. The invention also provides kits that are useful for performing the methods of the invention.12-31-2009
20090325196LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS - The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease. This diagnostic test serves to predict a patient's likelihood to respond to a specific drug treatment, in particular treatment with BLyS antagonists, either singly or in combination with other immune suppressive drugs12-31-2009
20090081707Human trk receptors and neurotrophic factor inhibitors - The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.03-26-2009
20100003704IN SITU detection of early stages and late stages HPV infection - Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and/or late HPV-associated or HPV-specific proteins or antibodies. Mononoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of invasive cervical cancer are provided. Cervical cancer biomarkers are identified and can be used in a detection method for early stage precancerous lesions as well as late stage cancer progression.01-07-2010
20090221001Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptor - Methods for identifying compounds that modulate the T1R1/T1R3 umami taste receptors are provided. These methods comprise screening for compounds that compete with lactisole for binding to and/or inhibiting the T1R1/T1R3 umami taste receptor.09-03-2009
20090208979Method for identifying antipsychotic drug candidates - The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.08-20-2009
20080261242Highly Sensitive System and Methods for Analysis of Troponin - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.10-23-2008
20090117593T. Cruzi-derived neurotrophic agents and methods of use therefor - The invention relates to 05-07-2009
20090253152NOVEL MUTANT IGFBP-3 MOLECULES THAT DO NOT BIND TO IGFs, BUT RETAIN THEIR ABILITY TO FUNCTIONALLY BIND IGFBP-3 RECEPTOR - There is disclosed novel mutant IGFBP-3 polypeptides and fragments thereof that have either no binding, or diminished binding to IGFs, yet retain their ability to bind to the human IGFBP-3 receptor (“P4.33”). The present invention provides novel mutant IGFBP-3 nucleic acid sequences, and expression systems. Additional exemplary embodiments provide for screening assays for identifying IGFBP-3 receptor antagonists or agonists, methods for modulating IGF-independent IGFBP-3 responses of cells expressing IGFBP-3 receptors, methods for inducing or potentiating apoptosis of cells expressing IGFBP-3 receptors, methods for treating solid tumors having cells expressing IGFBP-3 receptors, and compositions comprising polypeptides having either no binding, or diminished binding to IGFs, yet retain their ability to bind to the IGFBP-3 receptor.10-08-2009
20090220995MULTIPLE ADMINISTRATIONS OF UMBILICUS DERIVED CELLS - A method to determine the optimal administration protocol of allogeneic donor tissue to treat a disease in a human, using an animal model of human disease.09-03-2009
20090221002Methods of quantifying taste of compounds for food or beverages - Methods of quantifying the taste of compounds for food and beverages are provided. These methods comprise contacting the compounds with an isolated heteromeric receptor comprising at least one T1R1 polypeptide and at least one T1R3 polypeptide.09-03-2009
20090220996In vitro Assay Methods for Classifying Embryotoxicity of Compounds - The present disclosure provides methods useful for screening compounds and/or compositions, for example potential drug candidates. The results of the screening assays correlate to the effects of the compounds on the molecular and/or cellular level of the human body. Also disclosed are screening assays utilizing human embryonic stem cells RELICELL®hES of Indian origin. The methods disclosed herein correlate well with animal preclinical toxicity studies done in a clinical trial setup.09-03-2009
20090220997Stimulating G Protein-Coupled Receptors - This document provides methods and materials related to activating GPCRs. For example, methods and materials for activating GPCRs present on cells (e.g., human cell) as well as methods and materials for identifying GPCR agonists are provided.09-03-2009
20090208976Regulation of F1-ATPase Beta Subunit Cellular Location - It has been discovered that the ability of analogues to affect binding of a labeled β-casomorphin (an enterostatin antagonist) to recombinant rat F08-20-2009
20090208977MATERIALS AND METHODS FOR SPERM SEX SELECTION - Materials and Methods for the separation of X- and Y-chromosome bearing sperm, for example in a semen sample, are provided. The methods involve contacting the semen sample with a binding agent, such as an antibody, that specifically binds to an antigen that is specific for an X- or Y-chromosome. Kits for use in the methods are also provided.08-20-2009
20130137118INTEGRIN HETERODIMER AND A SUBUNIT THEREOF - A recombinant or isolated integrin heterodimer comprising a novel subunit α10 in association with a subunit β is described. The α10 integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit of α10 can be used as a marker or target of all types of cells, e.g. of chondrocytes, osteoblasts, and fibroblasts. The integrin or the subunit α10 thereof can be used as a marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.05-30-2013
20120142027Compositions and Methods for Modulating the Immune Response and Identifying Immunomodulators - The present invention provides compositions and methods for the identification of immunomodulators. The invention further provides an isolated complex comprising an UNC93B polypeptide and an UNC93B-dependent TLR polypeptide and methods of use thereof. The invention further provides methods of modulating immune system activity and methods of treating diseases characterized by aberrant immune system activity.06-07-2012
20100184093Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition - Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.07-22-2010
20120196301USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS - The present invention relates to the use of binding partners for 5-HT5 receptors for the treatment of neuropathological, in particular neurodegenerative and/or neuropsychiatric, disorders, which can occur, in particular, in cerebral ischemia, stroke, epilepsy and seizures in general, chronic schizophrenia, other psychotic disorders, dementia, in particular Alzheimer's dementia, demyelinizing disorders, in particular multiple sclerosis, and brain tumors. The invention also relates to processes for the identification and characterization of such binding partners, in particular in the form of screening processes.08-02-2012
20100261202METHOD FOR EFFICIENT PRODUCTION OF MONOCYTE-DERIVED MULTIPOTENT CELL (MOMC) - It is to provide a practical method for producing efficiently a large amount of MOMC, which is a multipotent cell which is very suitable for cell transplantation for organ regeneration. It was found that by culturing peripheral blood monocytes in vitro on fibronectin in the presence of SDF-1, MOMC can be produced more efficiently, and the present invention has been completed. Specifically, it is a method for producing MOMC by culturing in vitro peripheral blood monocytes expressing CD14 on fibronectin, wherein the in vitro culture is performed in the presence of SDF-1.10-14-2010
20100184094USE OF MDCK CELLS IN THE EVALUATION OF CHOLESTEROL MODULATORS - A novel use for MDCK cells in the evaluation of cholesterol modulators is provided. In particular, methods for detecting substances which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Such substances are of use in the treatment of individuals with hypercholesterolemia. The various assays may additionally be employed for studying NPC1L1 function.07-22-2010
20110003319Transgenic Trasnchromosomal Rodents for Making Human Antibodies - The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.01-06-2011
20100261201ASSAY FOR MONITORING ACTIVITY OF FRIZZLED RECEPTORS - The present invention relates to cell free assays for measuring receptor activity, especially for measuring a constitutive or a non-constitutive activity of frizzled receptors and uses thereof. The present invention further concerns a method for measuring a constitutive or non-constitutive activity of a frizzled receptor and a method for obtaining an active frizzled receptor ligand.10-14-2010
20100261203Methods and kits for screening transplant recipients and candidates - Methods and kits are provided for determining of immunoglobulin isotypes and subclasses in a subject. In general the subject is a human who is a transplant candidate recipient or recipient, has allergies, or has an autoimmune disease. The method involves analyzing a sample of a body fluid of a transplant candidate or recipient, allergy patient or autoimmune disease sufferer and correlating the relative amounts of each immunoglobulin isotype and subtype, such that the distribution of isotypes and subtypes is an indication of success of the transplant in the candidate and recipient or the prognosis of the autoimmune disease.10-14-2010
20100167316Enrichment of Tissue-Derived Adult Stem Cells Based on Retained Extracellular Matrix Material - Methods for enriching, detecting, or using adult stem cells through the use of recognition ligands that specifically bind to ECM components retained to the surfaces of adult stem cells are described. An ECM component such as hyaluronan that is retained to the surfaces of adult stem cells when removed from animal tissues can be used to detect a diverse population of adult stem cells based on the nature of the ECM niche region in which the adult stem cells normally reside. For example, a separation method such as magnetic separation can be used to detect and isolate or enrich adult stem cells based on a recognition ligand that is specific for an ECM component that is retained to the surfaces of adult stem cells to a greater degree than to other cells in the population.07-01-2010
20110104717METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.05-05-2011
20100216167METHODS FOR RELIEVING NEUROPATHIC PAIN BY MODULATING ALPHA 1G T-TYPE CALCIUM CHANNELS AND MICE LACKING ALPHA 1G T-TYPE CALCIUM CHANNELS - The present invention relates to a novel use of a transgenic mouse deficient in α1G T-type calcium channel as an animal model for the study of neuropathic diseases, more precisely, a novel use of a transgenic mouse having resistance against neuripathic pain as an animal model for the development of a therapeutic agent and a treatment method for human neuropathic diseases. The transgenic mouse deficient in α1G T-type calcium channel having resistance against neuropathic pain, provided by the present invention, can be effectively used for the development of a therapeutic agent and a treatment method for human neuropathic diseases.08-26-2010
20100184098METHODS FOR MEASURING ENZYME ACTIVITY - The invention relates to fluorescence methods for measuring enzyme activity, in particular enzyme cleaving and joining activities. The invention also relates to fluorogenic substrates which are useful for measuring enzyme activity and as in vitro and in vivo imaging probes.07-22-2010
20110059467CONTROLLED MODIFICATION OF SEMICONDUCTOR NANOCRYSTALS - A controlled valency semiconductor nanocrystal can have a desired number of compounds associated with it. The semiconductor nanocrystal can have exactly one compound associated with it, and the compound can have exactly one binding site for an affinity target. The semiconductor nanocrystal can be used to image single copies of cell-surface proteins.03-10-2011
20100151498Method of Diagnosing Asthenozoospermia - After sampling semen from healthy males and from patients whose chief complaint was infertility, the semen volume, sperm concentration, sperm motility rate, and sperm survival rate in each of the specimens were measured, sperm-bound SPMI was detected using an anti-SPMI antibody, and the amount and rate of SPMI binding were calculated. As a result, only patient specimens were found in the specimen group with amount and rate of SPMI binding above a certain level. Diagnosis of asthenozoospermia can be made by determining the amount and rate of SPMI binding.06-17-2010
20100255506PROCESS OF USING A TETRAZOLIUM SALT - Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkylammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings attached to the tetrazolium ring.10-07-2010
20100255505GENETICALLY MODIFIED STEM CELLS AND METHODS FOR IDENTIFYING TISSUES DIFFERENTIATED THEREFROM - Genetically modified stem cells and the selection of cells differentiated therefrom are disclosed. Particularly, the herein disclosed invention relates to stem cells or cells differentiated therefrom containing a copy of a stably inheritable expression construct that is suitable for the expression of transgenes in stem cells, wherein said construct comprises at least a double-feature constitutive promoter being operable both in stem cells and in differentiated tissues, the expression level thereof being subject to a tissue or cell type specific regulation in differentiated cells, and, optionally, under the control of said promoter, a transgene, wherein said transgene is expressed in the stem cell. Furthermore methods are disclosed to produce such stem cells, as well as specific uses of said stem cells in assay methods and in human therapy and in veterinary practice.10-07-2010
20100221753Prostate Cancer-Related Compositions, Methods and Kits Based on DNA Macroarray Proteomics Platforms - The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.09-02-2010
20100240072Cancer Imaging and Treatment - A compound, or a pharmaceutically acceptable salt or ester thereof, comprises the structure: [(P1-S109-23-2010
20100240071Assay for Detection of Transient Intracellular CA2+ - This invention relates to a simple end point assay for detection of transient intracellular Ca09-23-2010
20100255501METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE - Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.10-07-2010
20100255502Methods for Detecting and Inhibiting Angiogenesis - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.10-07-2010
20100255503MARKERS FOR DIAGNOSIS OF CANCER AND ITS USE - Disclosed herein are diagnostic markers CTHRC1, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.10-07-2010
20100255504Reactive Heterocycle-Substituted 7-Hydroxycoumarins and Their Conjugates - Chemically-reactive, water-soluble, heterocycle-substituted 7-hydroxycoumarin dyes, their bioconjugates and uses are described. The conjugates derived from reactive heterocycle-substituted 7-hydroxycoumarin dyes are used for analyzing biological compounds. These heterocycle-substituted 7-hydroxycoumarin dyes are particularly useful as fluorescent labels for biopolymer detection reagents, such as antibodies or nucleic acid probes. The dye-antibody conjugates of the invention are particularly useful for analyzing analytes using a flow cytometer equipped with a violet laser as an excitation source due to their strong absorption at 405 nm and high fluorescence quantum yield.10-07-2010
20090042221PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. With respect to the culturing of malignant cells, for example, it is believed (without any intention of being bound by the theory) that by maintaining the malignant cells within a multicellular particulate of the originating tissue, growth of the malignant cells themselves is facilitated versus the overgrowth of fibroblasts or other cells which tends to occur when suspended tumor cells are grown in culture. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. Growth of cells is monitored to ascertain the time to initiate the assay and to determine the growth rate of the cultured cells; sequence and timing of drug addition is also monitored and optimized. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.02-12-2009
20120142028BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS - The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an EGFR kinase inhibitor. These methods are based on the surprising discovery that the effectiveness of treatment with an EGFR kinase inhibitor is predicted by whether a patient's tumor cells express a high or a low level of the biomarkers vimentin and E-cadherin, such that patients whose tumors express a high level of at least one of the biomarkers vimentin and E-cadherin have a longer overall survival and progression free survival than patients whose tumors express a low level of both vimentin and E-cadherin. The present invention further provides a method for treating tumors or tumor metastases in a patient, comprising the steps of diagnosing a patient's likely responsiveness to an EGFR kinase inhibitor by assessing whether tumor cells express a high level of at least one of the biomarkers vimentin and E-cadherin, and administering to said patient a therapeutically effective amount of an EGFR kinase inhibitor (e.g. erlotinib), particularly when effectiveness of the inhibitor is predicted.06-07-2012
20120142029NUCLEIC ACIDS ENCODING A G-PROTEIN COUPLED RECEPTOR INVOLVED IN SENSORY TRANSDUCTION - The invention provides isolated nucleic acid and amino acid sequences of sensory cell specific G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sensory cell specific G-protein coupled receptors.06-07-2012
20090280508Methods and Reagents for Preparing and Using Immunological Agents Specific for P-Glycoprotein - This invention relates to immunological reagents and methods specific for a mammalian, transmembrane protein termed Pgp, having a non-specific efflux pump activity established in the art as being a component of clinically-important multidrug resistance in cancer patients undergoing chemotherapy. The invention provides methods for developing and using immunological reagents specific for certain mutant forms of Pgp and for wild-type Pgp in a conformation associated with substrate binding or in the presence of ATP depleting agents. The invention also provides improved methods for identifying and characterizing anticancer compounds.11-12-2009
20090275055Monoclonal Antibodies Specific to Denatured Human Class I Leucocyte Antigens - [PROBLEMS] To provide a monoclonal antibody simultaneously detectable the expression of all three kinds of HLA-A, HLA-B and HLA-C heavy chain proteins composing human class I leukocyte antigens (HLA class I) in denatured human tissue samples fixed by formalin and the like.11-05-2009
20110027807PROTEIN SPECIFIC TO PANCREATIC BETA CELLS IN ISLETS OF LANGERHANS AND APPLICATIONS THEREOF - The invention relates to protein ZnT-8 which is specifically expressed in the pancreatic beta cells in islets of Langerhans, to a polynucleotide encoding said protein which is involved in the maturation and exocytosis of insulin, and to the applications thereof, for example, for sorting and studying beta cells and for screening medicine acting on diabetes and hyperinsulinism.02-03-2011
20110027804IMMUNE SYSTEM MODELING DEVICES AND METHODS - Devices and methods are provided for detecting an immune reaction to a test agent using an immune modeling system comprising a barrier component configured to culture a biological barrier, an immune component configured to culture immune cells, and one or more inter-component microfluidic connections between the barrier component and the immune component. The system provides for culturing a biological barrier in the barrier component of the system, culturing immune cells in the immune component of the system, applying the test agent to the biological barrier, and monitoring the immune cells to detect an immune reaction to the test agent.02-03-2011
20080305498Biomarkers for Use in Vessel Disorders - The present invention relate to a method of diagnosing a subject having a vessel disorder. More particularly, a biological sample is obtained from a subject suspected of having a vessel disorder. A protein profile is determined or measured in the sample using procedures described herein, for example, mass spectrometry or immunodetection. The protein profile from the subject is compared to a protein profile in a healthy control, wherein an alteration in the levels of a protein of the profile in the subject compared to the healthy control is indicative of a vessel disorder.12-11-2008
20090111125Method for detecting mycobacterial infection - A method of detecting a surrogate marker for active tuberculosis involves obtaining first, second and third samples from a subject suspected of having active tuberculosis, diluting the first sample and exposing part of it to an immobilized mycolic acid antigen in a test vessel and part of it to an immobilized mycolic antigen in a control vessel. The second sample is exposed to mycolic acid antigen-containing liposomes and the third sample is exposed to liposomes not containing mycolic acid antigens. The second sample is added to the test vessel and the third to the control vessel and binding of antibodies to the mycolic acid and antigen in both the test and control vessel is detected. The degree of binding between the test and control vessels is compared and lesser binding in the test vessel is an indicator of the presence of antibodies to the mycolic acid antigen.04-30-2009
20100297671Method and Device for the Quantitative Determination of Analytes in Liquid Samples - The invention relates to a method and a device for the highly sensitive parallel detection and quantitative determination of analytes in liquid samples. According to said method, total internal reflection fluorescence (TIRF) is used in combination with a binding inhibition test on a specially coated support. The inventive method makes it possible to quickly analyze different types of liquids, such as drinking water, fruit juices, milk, serum, blood plasma, urine, etc., while allowing samples to be analyzed simultaneously regarding several different analytes, including hormones, antibiotics, pesticides, pharmaceuticals, drugs, and other molecules or molecular complexes, for example.11-25-2010
20110117574FLUORESCENCE BASED ASSAY TO DETECT SODIUM/CALCIUM EXCHANGER "FORWARD MODE" MODULATING COMPOUNDS - Transporters are an emerging target family with enormous potential, offering scientific and economic opportunities. The sodium/calcium exchanger is an important mechanism for removing Ca05-19-2011
20110129856APPARATUS AND METHOD FOR SEPARATING COMPONENTS - An apparatus for separating components and a method of separating components using the apparatus are provided. The apparatus includes: a main chamber which contains a sample that is separated into a plurality of layers by a centrifugal force; a component separating chamber which is connected to the main chamber, and receives a specific layer including specific components among the plurality of layers; a first channel which connects the component separating chamber to the main chamber; and a first channel valve which is disposed in the first channel to control a liquid flowing through the first channel.06-02-2011
20100297673METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY - A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity.11-25-2010
20100304406Protein Phosphorylation by Serine/Threonine Kinases in Insulin Signaling Pathways - The invention discloses 137 novel phosphorylation sites identified in insulin signaling pathways, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.12-02-2010
20110212469Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.09-01-2011
20110111433PIEZOELECTRICAL CHARACTERIZATION OF MATERIALS - One aspect of the disclosure is a method of characterizing a surface. In an exemplary embodiment, the method includes: (a) positioning a piezoelectric sensor near the surface; (b) obtaining by the sensor a resonant acoustic profile (RAP) of the surface; and (c) analyzing the obtained RAP to characterize the surface. The piezoelectric sensor has an interacting layer, which is adapted for binding to the surface to be characterized. In one embodiment, the characterized surface and the interacting layer are of about the same size.05-12-2011
20100311082Stable Cell Lines and Methods for Evaluating Gastrointestinal Absorption of Chemicals - Nucleic acids and vectors for interfering with the expression of membrane efflux transport proteins in cells that express such proteins are provided. Also provided are cells and cell lines comprising such nucleic acids and vectors. Methods for screening chemicals and biomolecules for gastrointestinal absorption in animals, and kits for practicing such methods are also provided.12-09-2010
20110111429FLUORESCENT CARBAZOLE COMPOUNDS FOR CANCER DIAGNOSIS - A compound of formula (I):05-12-2011
20110111434COLON STEM CELLS ASSOCIATED WITH COLITISAND COLORECTAL CANCER AND METHODS OF USE - The disclosure provides methods of isolating and propagating self-renewing colonic stem/progenitor cells (CS/PCs) that express aldehyde dehydrogenase (ALDH1), from colon cancer and colitis tissues, as well as from normal colon tissue, methods of identifying agents for modulating the proliferative status of such cells, an methods of screening patients having colitis for an increased risk of colorectal cancer. Novel methods of adherent cell culture propagation of CS/PC involving use of colon-specific fibroblastic stromal cells (CFSt) {i.e. the “niche” cells) as support cells (e.g., “feeder cells”). The present disclosure encompasses an isolated mammalian pluripotent colon epithelial stem/progenitor cell (CS/PC), or a population of said cells, where each CS/PC may comprise a detectable marker, where the detectable marker is aldehyde dehydrogenase 1 (ALDH1), and where the isolated population of mammalian pluripotent CS/PCs is substantially free of cells that do not have the detectable ALDH 1 marker. The disclosure encompasses further provides methods for determining the prognosis for a patient for developing a colon cancer, the method detecting the presence of at least one marker in a tissue section from a patient, the marker or plurality of markers indicating the presence of a pluripotent colon epithelial stem/progenitor cells and indicating the prognosis of the patient for developing a colon cancer.05-12-2011
20110117573CELL DIVISION MARKER - This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age.05-19-2011
20110008802TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS - TNFα gene expression can be used as a biomarker of a cell's sensitivity to antagonists of inhibitor of apoptosis proteins (IAPs). Methods of the invention are useful for screening patients to identify those who could benefit from administration of an IAP antagonist to treat various malignant or benign tumors, benign proliferative diseases, or autoimmune diseases.01-13-2011
20110008801METHODS FOR MEASURING CELL-CELL OR CELL-MATRIX ADHESIVE FORCES AND COMPOUNDS FOR DISRUPTING ADHESIVE FORCES IN BIOLOGICAL SYSTEMS - The invention provides an atomic force microscope-based bioassay, assisted by thermodynamic characterizations to quickly and accurately screen for compounds that disrupt cell-cell or cell-substrate interactions.01-13-2011
20110033874BIOMARKERS - The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring ANP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection. Also provided are antibodies useful in the methods of the invention.02-10-2011
20100184096SCREENING METHODS USING SITOSTEROLEMIA SUSCEPTIBILITY GENE (SSG) POLYPEPTIDES - The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.07-22-2010
20110039279METHODS AND COMPOSITIONS FOR DIAGNOSING BREAST CANCER - Mammastatin has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated Mammastatin.02-17-2011
20110039278DEVICE AND METHODS FOR THE IMMUNOLOGICAL IDENTIFICATION OF CEREBROSPINAL FLUID - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.02-17-2011
20100173333METHOD OF SCREENING CANDIDATE COMPOUNDS FOR SUSCEPTIBILITY TO BILIARY EXCRETION - A method of screening a candidate compound for susceptibility to biliary excretion. The method includes the steps of providing a culture of hepatocytes, the culture having at least one bile canaliculus; exposing a candidate compound to the culture; and determining an amount of candidate compound in the at least one bile canaliculus, the amount of candidate compound in the at least one bile canaliculus indicating the susceptibility of the candidate compound to biliary excretion. Optionally, the culture of hepatocytes is a long-term culture in a sandwich configuration. The method is particularly applicable to the screening of multiple candidate compounds in a single effort.07-08-2010
20110244485ANTI-TUNA VASA ANTIBODY - An object of the present invention is to provide a means for distinguishing between a germ cell derived from a donor (tuna) and a germ cell derived from a recipient in a method for inducing differentiation of a tuna germ cell, wherein a primordial germ cell derived from the tuna is transplanted into an early embryo of the heterologous recipient fish. The present inventors compared a Vasa amino acid sequence of bluefin tuna with those of other fish (black skipjack, skipjack, chub mackerel, blue mackerel, round frigate mackerel and frigate mackerel), identified amino acid sequence regions specific to bluefin tuna, and, by using the amino acid sequences specific to bluefin tuna as antigens, successfully produced monoclonal antibodies specifically recognizing primordial germ cells, spermatogonia, oogonia or oocytes derived from bluefin tuna, thus accomplishing the present invention.10-06-2011
20090142779METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor.06-04-2009
20110117575ISOLATION AND/OR IDENTIFICATION OF STEM CELLS HAVING ADIPOCYTIC, CHONDROCYTIC AND PANCREATIC DIFFERENTIATION POTENTIAL - The present invention relates to a method for isolating and/or identifying stem cells having adipocytic, chondrocytic and pancreatic differentiation potential, wherein an antibody is used that binds to the antigen TNAP, alone or in combination with an antibody that binds to the cell surface antigen CD56. The invention also relates to stem cells isolated by the method according to the invention for treating defects or damages or diseases in bone or cartilage of a patient in need thereof.05-19-2011
20090142778COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE - Compositions and methods for the therapy and diagnosis of Inflammatory Bowel Disease (IBD), including Crohn's Disease and Ulcerative Colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of IBD.06-04-2009
20110086366METHODS FOR ASSESSING THE RISK OF ADVERSE EVENTS UPON TREATMENT WITH IGG4 ANTIBODIES - The invention relates to methods and kits for assessing the risk, for an individual, of developing an adverse event upon treatment with a therapeutic antibody which is capable of Fab-arm exchange, said method comprising the steps of: a) providing a sample from an individual who is a candidate for treatment with said therapeutic antibody, b) assaying said sample for the presence of circulating IgG4 antibodies that binds an antigen known or suspected to be associated with a causative agent of said adverse event, and c) assessing, on the basis of the outcome of the assay of step b), the risk that the individual will develop said adverse event upon treatment with the therapeutic antibody, wherein the risk of development of said adverse event increases with increased level of said circulating IgG4 antibodies.04-14-2011
20110244487METHODS FOR TESTING BINDING OF A LIGAND TO A G PROTEIN-COUPLED RECEPTOR - The present invention relates to methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the methods of the invention are useful in high throughput screening for ligands which bind to G Protein-Coupled Receptors.10-06-2011
20110244484METHOD OF DIAGNOSING ALZHEIMER'S DISEASE USING GIANT MAGNETORESISTANCE SENSOR AND MAGNETIC BEAD-POLYPROTEIN COMPLEX FOR DIAGNOSING ALZHEIMER'S DISEASE - Provided are a method of diagnosing Alzheimer's disease using a giant magnetoresistance sensor and a magnetic bead-polyprotein complex for diagnosing Alzheimer's disease. The method of diagnosing Alzheimer's disease using the giant magnetoresistance sensor may be applied to diagnose Alzheimer's disease more easily and simply using the giant magnetoresistance sensor than using conventional fluorescent materials or genetic analyses, and the magnetic bead-polyprotein complex may be mass-produced as a diagnostic biosensor for Alzheimer's disease, and thus to be useful to monitor and treat Alzheimer's disease.10-06-2011
20110129855Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody.06-02-2011
20110143374Methods to Identify Modulators of the Interaction Between Dextromethorphan and the Bitter Taste Receptor TAS2R46 - TAS2R46 was identified as a dextromethorphan-binding bitter taste receptor. Novel methods to identify modulators and in particular inhibitors to the bitter taste of dextromethorphan are provided.06-16-2011
20110143375BIOMARKER DETECTION PROCESS AND ASSAY OF NEUROLOGICAL CONDITION - The subject invention provides a robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The invention provides measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.06-16-2011
20110212468BIOMARKERS AND METHODS FOR DETERMINING DISEASE PROGRESSION IN NONALCOHOLIC STEATOHEPATITIS (NASH) - Diets high in saturated fat and fructose have been implicated in the development of obesity and nonalcoholic steatohepatitis (NASH) in humans. Provided herein are biomarkers, methods, and animal models useful for the investigation and non-invasive detection of NASH, including a non-invasive biomarker that could be used to establish disease severity, follow progression, and evaluate response to treatment in clinical trials for this increasingly prevalent disease.09-01-2011
20100216166TARGET ACTIVATED MICROTRANSFER - A device for performing target activated transfer that includes a mounting surface for mounting a tissue sample; and a light source positioned to substantially uniformly irradiate both stained and unstained regions of the tissue sample with light energy that activates the reagent to selectively adhere the stained regions to a transfer surface. Also described is an automated system for transferring tissue from a tissue sample to a transfer substrate. The system includes means for holding a tissue section that includes targets specifically stained with an absorptive stain thereby resulting in a stained tissue surface, and a flexible transfer film that includes a lower thermoplastic layer in sufficient thermal contact with the stained tissue surface; an irradiating assembly configured to provide a predetermined uniform light dose to the entire tissue section; and means for applying a constant pressure to the transfer film during irradiation.08-26-2010
20100015638Method for production of antibody directed against cell membrane surface antigen epitope and assaying method - Disclosed are a method for determining the affinity of an antibody capable of binding to a cell membrane surface antigen for the antigen; and a method for assaying or screening an antibody capable of binding to a cell membrane surface antigen by utilizing the determination method. In the determination of the affinity of the antibody for the antigen, floating cells presenting the antigen on the surface of the cell membrane thereof are used and the B/F separation of the cells is made by centrifugation or on a filter through which the cells cannot pass.01-21-2010
20110244486METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF DIABETES - Methods, assays and compositions for the diagnosis and treatment of diabetes, in which the glutamate transporters and/or receptors expressed in pancreatic islet cells are used as therapeutic targets or tools for the identification or treatment of individuals suffering from or susceptible to diabetes.10-06-2011
20090035791Neural Colony Forming Assay - A neural colony forming cell (NCFC) assay is described. The assay allows one to distinguish neural stem cells from neural progenitor cells. In one embodiment, the present invention provides a method for identifying neural stem cells or neural progenitor cells comprising: (a) suspending neural cells in a semi-solid medium which supports the growth of neural cells; (b) plating the cells in the semi-solid medium at a density that allows for the production of colonies; (c) culturing the plated cells until size differences can be discerned between the colonies; and (d) estimating colony size wherein the larger colonies are likely produced by neural stem cells and wherein the small colonies are likely produced by neural progenitor cells In alternate embodiments, NSC can be distinguished from neural progenitor cells by determining the morphology or antigen expression of the colonies.02-05-2009
20100068733pH-Sensitive Fluorescent Probe - A compound represented by the following general formula (I):03-18-2010
20100055719Screening method for identifying new aminoacyl-tRNA synthetase inhibitors - The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacyl-tRNA synthetase and does not affect to its cellular ortholog, resulting in that said substance is a candidate to drug.03-04-2010
20110097741PARTIAL T1R2 NUCLEIC ACID SEQUENCE, RECEPTOR PROTEIN AND ITS USE IN SCREENING ASSAYS - A novel sweet receptor protein, corresponding nucleic acid sequence, expression vectors, transfected host cells, and screening methods for modulators including ligands of the sweet taste response employing the aforementioned are provided.04-28-2011
20110097742CONTRAST AGENTS, METHODS FOR PREPARING CONTRAST AGENTS, AND METHODS OF IMAGING - Embodiments of the present disclosure provide for contrast agents, methods of making contrast agents, and methods of using contrast agents, and the like.04-28-2011
20110250618BIOMARKERS AND ASSAYS FOR DIABETES - The present invention is directed to novel biomarkers and combinations thereof. The present invention also provides assays and data evaluation methods related to the detection and monitoring of diseases, particularly, diabetes. In particular, the biomakers in accordance with the present invention include, but are not limited to, modified forms of nominally wild-type proteins, such as Gc-Globulin or GcG (also known as Vitamin D binding protein), beta-2-microglobulin (b2m), cystatin C (cysC), Albumin and Hem A&B. Particular forms of diabetes contemplated by the methods of the present invention include, but are not limited to, type 1 diabetes (T1D), type 2 diabetes (T2DM), pre-T1D and pre-T2DM. The present invention also provides methods of detecting multiple biomarkers in a single assay and to employ data evaluation methods that is able to accurately use these data in the determination and monitoring of diseases, such as diabetes.10-13-2011
20110177528METHODS FOR DETECTING AND INHIBITING ANGIOGENESIS - The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.07-21-2011
20100068732CLONED GLUCAGON-LIKE PEPTIDE-2 RECEPTORS - The invention relates to nucleotides and amino acid sequences encoding Glucagon-like peptide-2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.03-18-2010
20110081661Modified photoproteins with increased affinity for calcium and enhanced bioluminescence and uses thereof - The present invention provides modified photoproteins, e.g., modified Clytin, having an increased affinity for calcium as well as an enhanced bioluminescence and their use as calcium indicators in reporter gene systems and in cell-based assays.04-07-2011
20110151484hERG MUTANTS AND USES THEREOF - An isolated nucleic acid molecule capable of expressing an human ether-à-go-go related gene (hERG) mutant that enhances hERG inactivation, wherein the mutation is not located in the vicinity of the drug-binding pocket within the cavity of the ion conduction pore of the hERG protein. Use of the isolated nucleic acid molecule in an assay for screening potential drug binding to hERG protein.06-23-2011
20090215083SELECTING, CULTURING AND CREATING LINEAGE COMMITTED HEMATOPOIETIC STEM CELLS - The present invention provides a method for selecting hematopoietic stem cells (HSCs) comprising providing an agent which binds to α9β1 integrin on the cell surface to a population of cells including HSCs and separating HSCs by virtue of the binding agent. The invention also provides a method of culturing a population of HSCs in the presence of an agent which binds to α9β1, wherein the agent inhibits differentiation of the HSCs. The invention also provides a method of producing a population of lineage committed cells comprising culturing HSCs in the presence of an agent which inhibits or prevents binding to α9β1.08-27-2009
20110104715CYTOTOXIC PEPTIDES AND PEPTIDOMIMETICS BASED THEREON, AND METHODS FOR USE THEREOF - In accordance with the present invention, it has been discovered that the β-amyloid precursor protein (APP), and two APP-like proteins (APLP1 and APLP2) are proteolytically cleaved by caspases in the C terminus to generate an approximately 31 amino acid peptide. It has been further discovered that the resultant C-terminal peptide is a potent inducer of apoptosis. Both caspase-cleaved APP and activated caspase-9 is present in brains of Alzheimer's disease patients but not in control brains. These findings indicate that caspase cleavage of APP and APP-like proteins leads to the generation of apoptotic peptides, which may contribute to the neuronal death associated with Alzheimer's disease. Accordingly, there are provided compositions and methods for modulating apoptosis.05-05-2011
20110081663Molecular Probe for Imaging of Pancreatic Islets and Use of the Same - A molecular probe for imaging of pancreatic islets is provided. The molecular probe includes a polypeptide represented by the following formula (1), or a polypeptide that has a homology with the foregoing polypeptide.04-07-2011
20110081662SCREENING METHODS FOR BONE MORPHOGENETIC MIMETICS - Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions.04-07-2011
20110065129INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION - This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.03-17-2011
20110076696CARDIOVASCULAR SAFETY ASSAY - The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during the development of new therapeutics and other agents.03-31-2011
20120202221NATURAL PEPTIDE AND DERIVATIVES AS MODULATORS OF GPCR GPR1 AND USES THEREOF - The invention relates to the identification of Humanin and derivatives thereof as ligands of the GPR1 GPCR (G-protein coupled receptor). The invention encompasses the use of the interaction of GPR1 polypeptides and Humanin polypeptides as the basis of screening assays for agents that modulate the activity of the GPR1 receptor. The invention also encompasses diagnostic assays based upon the GPR1/Humanin polypeptide interaction, as well as kits for performing diagnostic and screening assays.08-09-2012
20120149036BIOASSAY METHOD FOR ANTIBODY AGAINST THYROID-STIMULATING HORMONE RECEPTOR, MEASUREMENT KIT FOR THE ANTIBODY, AND NOVEL GENETICALLY MODIFIED CELL FOR USE IN THE BIOASSAY METHOD OR THE MEASUREMENT KIT - The present invention provides a method and a kit for assaying a TSH receptor antibody, which are easy to manipulate and are safe. Specifically, the present invention provides a composition comprising a genetically modified cell forced to co-express a TSH receptor, a cyclic nucleotide responsive calcium channel, and a luminescent protein aequorin. Use of the composition enables the assay of a TSH receptor antibody contained in a sample.06-14-2012
20120149035MODULAR POINT-OF-CARE DEVICES, SYSTEMS, AND USES THEREOF - The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.06-14-2012
20110151483Mammalian Sweet and Amino Acid Heterodimeric Taste Receptors Comprising T1R3 and T1R1 - The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising T1R3 and T1R1, two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.06-23-2011
20090023159Method for the in vitro diagnosis of alzheimer's disease using a monoclonal antibody - The invention relates to a method for the in vitro diagnosis of Alzheimer's disease using a monoclonal antibody. Said antibody can bind at least to amino acids 12-16 of the β-amyloid peptide, specifically detecting the neuritic plaques which are characteristic of Alzheimer's disease, without detecting diffuse plaques which are not defining characteristics of the disease. Within the neuritic plaques, the monoclonal antibody can detect a different sub-group in the composition of the different deposited isoforms of the β-amyloid peptide, which is associated with the disease progression stage. In addition, the antibody can bind to isoforms of the β-amyloid peptide in biological fluids such as urine. As a result, the inventive monoclonal antibody, the cell lines that produce said antibody and compositions containing same can be used in the in vitro diagnosis of Alzheimer's disease and in determining the disease progression stage.01-22-2009
20110151485METHOD FOR SCREENING FOR ANTIANGIOGENIC AGENT, AND METHOD FOR SCREENING FOR ANTIANGIOGENIC SIGNAL GENE - Disclosed are a method for screening for an antiangiogenic agent and a method for screening for an antiangiogenic gene, both of which are achieved by detecting an antiangiogenic signal within a short time by a simple means. The method for screening for an antiangiogenic agent comprises: a candidate compound administration step of administering a candidate compound for the antiangiogenic agent to a vascular endothelial cell or a cultured cell derived from a vascular endothelial cell; a cell-maintaining step of maintaining the vascular endothelial cell or the cultured cell derived from the vascular endothelial cell to which the candidate compound has been administered; and a signal detection step of detecting the phosphorylation of a protein phosphorylated by the administration of endostatin.06-23-2011
20090317835DEVICE FOR SAMPLING CELLS BY CONTACT - A microtechnological device (12-24-2009
20090291458Method for Determining the Status of an Individual - Methods of determining status of an individual based on the use of biological specimen and analysis of reference population of cells are described.11-26-2009
20080305499Anti-Synoviolin Antibody - The present invention relates to an antibody against synoviolin or a fragment thereof for providing a monoclonal antibody capable of recognizing a part of synoviolin, which monoclonal antibody is capable of inhibiting the auto-ubiquitination of synoviolin.12-11-2008
20110256555USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.10-20-2011
20080268472High throughput assay systems and methods for identifying agents that alter expression of cellular proteins - Disclosed are high throughput assay systems and methods for identifying agents that alter the level of expression of proteins in mammalian cells, particularly integral membrane proteins.10-30-2008
20100297672HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF TROPONIN - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin.11-25-2010
20120202222ENZYME FRAGMENT COMPLEMENTATION ASSAYS FOR MONITORING THE ACTIVATION OF THE VOLTAGE-GATED POTASSIUM ION CHANNEL HERG - The present invention provides methods and cell based assays for testing for the binding of a ligand to a human Ether-a-go-go-related (hERG) voltage-gated potassium ion channel protein in an enzyme complementation assay. The invention is of particular use in toxicological and drug screening, particularly for high throughput screening.08-09-2012
20120276554ISOLATION AND USE OF RYANODINE RECEPTORS - The genes encoding ryanodine receptor homologs have been characterized from multiple insect families. The genes and their corresponding polypeptides have a number of uses including but not limited to the development of screens to identify insecticidally active compounds. Methods are outlined for overcoming toxic effects of expressing recombinant proteins in host cells.11-01-2012
20110020843LABEL-FREE METHODS RELATED TO PHOSPHODIESTERASES - 196. Disclosed are methods of incubating cells on biosensors, and methods using the disclosed incubation techniques to identify PDE4 modulators.01-27-2011
20110020842eEF2K Assays for Identifying Compounds that Inhibit eEF2K Activity - Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein.01-27-2011
20110053184Nucleic Acid Encoding A Haplotype of Human T2R Receptor hT2R50 - The present invention relates to the discovery of a novel haplotype of the human taste receptor hT2R50 in the T2R taste receptor family that responds to particular bitter ligands, i.e., 2-acetylpyrazine and ethylpyrazine. The present invention also relates to the use of this novel haplotype in assays for identifying ligands that modulate the activation of the hT250 taste receptor. These compounds potentially may be used as additives in foods, beverages and medicinals for modifying (blocking) hT2R50-associated bitter taste.03-03-2011
20110053182DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS - The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions comprising one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening for therapeutically useful PCDGF agents are also provided.03-03-2011
20110027806FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors.02-03-2011
20110027805ACPL-RELATED ASSAYS - The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.02-03-2011
20110111430METHOD FOR DIAGNOSING LIVER FIBROSIS - Provided herein are methods and devices for nonsurgically predicting, diagnosing, and monitoring liver fibrosis in an individual. Methods utilize biomarkers, age and sex to determine a diagnostic score. The diagnostic score is then used to predict, diagnose, or assess liver fibrosis in the individual.05-12-2011
20110111431METHOD FOR IDENTIFYING PRE-NEOPLASTIC AND/OR NEOPLASTIC STATES IN MAMMALS - The present invention relates to methods of identifying pre-neoplastic and/or neoplastic states in mammals and in particular to a method for identifying pre-neoplastic and neoplastic cells in tissues and body fluids, based on differential expression of purinergic receptors in these cells.05-12-2011
20110111432DIAGNOSTIC METHOD FOR PEANUT ALLERGY - The present invention provides novel methods and tools to differentiate between true allergy and false positive allergy tests. In particular, parameters that can be statistically associated with true peanut allergy have been identified. These include wheal size in response to a skin prick test and total IgE. Further parameters may be measured for greater certainty.05-12-2011
20110136146BIOASSAY FOR POLYQ PROTEIN - The present invention relates to bioassays for mutated polyQ protein associated with disease and their use as diagnostic tools, for monitoring disease progression or for monitoring the efficacy of treatment of the disease. In a preferred embodiment the polyQ-protein is polyQ-huntingtin.06-09-2011
20110136145METHODS FOR PROMOTING FUSION AND REPROGRAMMING OF SOMATIC CELLS - The invention features methods for reprogramming somatic cells by treating the cells with one or more agents to induce de-differentiation, in particular by targeting demethylase and methyltransferase genes. The invention also features methods of monitoring somatic cell fusion and reprogramming and methods of identifying agents that alter somatic cell fusion and reprogramming. The invention also features reprogrammed cells and kits.06-09-2011
20100330592METHOD FOR DETECTING TRUNCATED MOLECULES - Exemplary disclosed embodiments may comprise, for example, providing a sample potentially comprising a native molecule and/or a truncated molecule. The native molecule comprises at least first and second regions recognized by first and second specific binding moieties, and the truncated molecule includes only one of the first and second regions. A composition comprising first and second specific binding moieties is applied to the sample in a manner effective to form first and second specific binding pairs with the first and second regions. For example, if the molecule is a protein, such as HER2, the protein may have a first epitope and a second epitope. Once a specific binding pair is formed, the pair must be visualized. Certain disclosed embodiments comprise a direct detection method whereby primary antibodies are coupled to signal generating moieties. Alternatively, signal amplification techniques can be used to visualize a specific binding pair.12-30-2010
20100330591GPCR Expressing Cell Lines and Antibodies - The present invention provides expression vectors that facilitate high levels of expression of GPCR proteins. Encompassed by the invention are methods and compositions for recombinant cell lines expressing GPCR proteins with the aid of the expression vectors of the instant invention. The recombinant cell lines of the instant invention express GPCR proteins at levels of at least about 150,000 copies of the protein per cell. The present invention also provides methods and compositions for raising antibodies against GPCR proteins using the high expressing recombinant cells of the instant invention.12-30-2010
20100196930CELL BASED ASSAYS FOR THE TRIGLYCERIDE SYNTHESIS PATHWAY - A method for identifying a compound which modulates the activity of acyl-coA: diacylglycerol acyltransferase comprises the steps of contacting a stable isotope labeled fatty acid with cells in either presence or absence of the compound, extracting the cells with isopropyl alcohol, and determining the level of a stable isotope labeled triglyceride in the presence or absence of the compound; wherein a change in the level of the stable isotope labeled triglyceride indicates that the compound modulates the DGAT activity.08-05-2010
20100196928Gene specific to cancer and diagnosis kit using the same - The present invention provides a new additional identification of a gene related to cancer expression and a diagnostic kit using the same.08-05-2010
20100120070PRECISE EFFICACY ASSAY METHODS FOR ACTIVE AGENTS INCLUDING CHEMOTHERAPEUTIC AGENTS - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique of the present invention is also useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents.05-13-2010
20090203048Screening Assays for Antioxidants and Antiproliferative Compounds - Provided are screening assays for identifying and evaluating compounds with antioxidant and/or antiproliferative activities.08-13-2009
20090203049BETA INTEGRIN GENE AND PROTEIN - Recombinant materials for the production of β integrin protein characteristic of 08-13-2009
2009020304788kDa tumorigenic growth factor and antagonists - This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.08-13-2009
20090203046METHODS FOR IDENTIFYING PURKINJE CELLS USING THE CORL2 GENE AS A TARGET - Total RNAs were prepared from the ventral and dorsal regions of embryonic day 12.5 mouse mesencephalon, and a cDNA fragment was obtained by the subtraction method (N-RDA). The full-length cDNA was cloned and the nucleotide sequence was determined. The gene was named Corl2. The result of homology search showed that about 850 residues of Corl2 exhibited homology to the XM_355050 sequence deposited in GenBank; however, the remaining ˜150 residues showed no homology. Thus, Corl2 was demonstrated to be a novel gene. The Corl2 expression in various mouse organs was analyzed by RT-PCR, and the result showed that Corl2 expression was specific to brain. The result of immunostaining day 12.5 embryos and postnatal day 12 brains demonstrated that Corl2 is useful as a Purkinje cell marker at any differentiation stages.08-13-2009
20090197284Analysis of Proteins from Biological Fluids Using Mass Spectrometric Immunoassay - Presented herein are methods, devices and kits for the mass spectrometric immunoassay (MSIA) of proteins present in complex biological fluids or extracts. Pipettor tips containing porous solid supports that are covalently derivatized with affinity ligand and used to extract specific proteins and their variants from various biological fluids. Nonspecifically bound compounds are rinsed from the extraction devices using a series of buffer and water rinses, after which the wild type protein (and/or its variants) are eluted directly onto a target in preparation for analysis such as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Mass spectrometry of the eluted sample then follows with the retained proteins identified via accurate molecular mass determination. Protein and variant levels can be determined using quantitative methods in which the protein/variant signals are normalized to signals of internal reference standard species (either doped into the samples prior to the MSIA analysis, or other endogenous protein co-extracted with the target proteins) and the values compared to a working curves constructed from samples containing known concentrations of the protein or variants. Such MSIA devices, kits and methods have significant application in the fields of; basic research and development, proteomics, protein structural characterization, drug discovery, drug-target discovery, therapeutic monitoring, clinical monitoring and diagnostics, as well as in the high throughput screening of large populations to establish and recognize protein/variant patterns that are able to differentiate healthy from diseased states.08-06-2009
20110189703High Throughput Cell-Based Assays, Methods of Use and Kits - In the present invention cells are placed in a multiwell plate and grown. When the assay is to be performed, one uses gravity to wash away any unbound ligands rather than vacuum or centrifugation. The cells are then examined to detect the bound ligand. To perform the washing step(s) the plate is placed into a carrier plate having open wells in register with the wells of the filter plate or one may use a wicking device or an underdrain attached to the bottom of the filter plate. Sufficient wash liquid is added to allow for filtration by the effect of gravity to occur. Cells are retained within the wells at a rate of 4 times that of other rapid methods.08-04-2011
20120309027QUANTITATIVE PEPTIDE ANALYSIS BY MASS SPECTROMETRY - A method for determining the concentration ratio in a sample of a target peptide to a reference peptide that is chemically identical with the target peptide, but labeled by isotopes, acquires mass spectra of the target and reference peptides. One of a plurality of families of superimposed bell-shaped curves which is a best fit to ion current peak groups of the target and reference peptides in the mass spectra is determined by varying parameters of the families. In each family, each bell-shaped curve has a predetermined height, the curves have fixed distances from each other and the relative curve heights and curve distances in the families are individually calculated from an elemental composition of the peptides and an isotope abundance distribution of elements composing the peptides, taking into account purity of the isotopes. The concentration ratio is then determined from the parameters of the best fit.12-06-2012
20120309026METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.12-06-2012
20110143372ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.06-16-2011
20100028912IMAGING USING RADIOACTIVE MONOCATIONS IN COMBINATION WITH A RECEPTOR BINDING LIGAND THAT STIMULATES THE INFLUX OF CATIONS - A novel method of imaging, comprising administration of a radioactive mono-cation, such as, for example, 02-04-2010
20100028913NOVEL CARBOHYDRATE FROM HUMAN CELLS AND METHODS FOR ANALYSIS AND MODIFICATION THEREOF - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.02-04-2010
20080318252Rapid assay to test anti-cancer drugs under physiological conditions - This invention relates to an assay that allows for the rapid determination of the activity of a given drug against leukemic cells either taken from a patient or derived from a cell line. The assay is performed in the presence of whole blood or serum.12-25-2008
20100221751METHOD OF SCREENING ENDOTHELIAL CELLS FOR ANGIOGENIC CAPABILITY - Provided is a method of screening a primary endothelial cell population for angiogenesis capability comprising: (a) measuring the percentage of cells that are positive for VEGF R2 and CD34, the level of VEGF R2, or measuring the VEGF R2 to VEGF R1 ratio in the population; and (b) selecting those populations where the measured percentage or the measured ratio is over a threshold value.09-02-2010
20090317833Screening Method - The present invention provides a method of screening for a drug for the prophylaxis or treatment of at least one disease selected from the group consisting of cardiac disease, autoimmune disease, inflammatory disease, central nervous system disease, infectious disease, sepsis, severe sepsis and septic shock, which includes selecting a substance that binds to an intracellular region of TLR4, and inhibits signal transduction from said molecule, and a kit for this method, which contains (1) a cell that expresses wild-type TLR4 and (2) a cell that expresses a mutant TLR4, and which can detect a signal from TLR4 with expression of a reporter gene as an index.12-24-2009
20090221003PROCEDURE FOR THE GENERATION OF A HIGH PRODUCER CELL LINE FOR THE EXPRESSION OF A RECOMBINANT ANTI-CD34 ANTIBODY - The present invention relates to cell capture assay for the selection of a high producer cell line expressing anti-CD34 antibodies that recognize the CD34 membrane-protein in the cell membrane. The monoclonal antibody secreted by the hybridoma cell line 9C5/9069 binds to human CD34 and is used to isolate stem cells. The DNA sequences encoding for the antibody heavy and light chain have been identified, isolated from the hybridoma cells and cloned into appropriate expression vectors. After co-transfection of the heavy and light chain genes into HEK293T or in CHO cells either conditioned medium or purified antibody were assessed for binding to CD34 protein located in the cell membrane in different cell capture assays. The binding of the antibody to CD34-positive cells could be shown with these assays for several cell lines.09-03-2009
20090123947Analytical Sandwich Test for determining NT-proBNP - The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. The epitopes recognized by the antibodies can slightly overlap.05-14-2009
20120040373Integrated Diagnosis of Heparin-Induced Thrombocytopenia - Disclosed are methods for the early detection of heparin-induced thrombocytopenia comprising the quantitative detection of chemokine platelet factor-heparin complexes, autoantibodies to such complexes, and platelet activation. Also disclosed are assays to detect the propensity of a subject to develop heparin-induced thrombocytopenia.02-16-2012
20120040374METHOD FOR DETECTING RENAL DISEASE COMPRISING MEASURING HUMAN MEGALIN IN URINE - This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.02-16-2012
20100285504MONOCLONAL ANTIBODY WHICH BINDS MET IN FORMALIN-FIXED AND PARAFFIN-EMBEDDED TISSUES AND RELATED METHODS - In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.11-11-2010
20080268470METHODS OF SELECTING CELL CLONES - The invention describes novel methods for selecting cell clones which produce high amounts of protein of interest. In one method the amount of protein is measured before the cells are passaged for the first time. In another method a high throughput automated platform is used under sterile environment conditions with class A particle load of less than 100 particles per m3.10-30-2008
20100184092Methods and Compositions for Detecting Receptor-Ligand Interactions in Single Cells - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.07-22-2010
20090298095Immortalization of cells including neuronal cells - The instant invention provides methods for immortalizing cells. The invention further provides immortalized cell lines, e.g., neuronal cell lines, and methods of using these cell lines in screening assays.12-03-2009
20100196929STABILISATION OF THE PHENOTYPIC PROPERTIES OF ISOLATED PRIMARY CELLS - The invention provides a method for stabilisation of phenotypic properties of isolated primary cells comprising modulating at least two epigenetic modifications in said cells.08-05-2010
20090191574Methods, Products and Treatments for Diabetes - The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.07-30-2009
20100015640Nucleic Acid, Polypeptide and Its Use - Novel chimeric proteins functional to screen for umami taste modulators, the corresponding nucleic acid sequences, expression vectors, transfected host cells, and screening methods for modulators and enhancers of the umami taste response employing the aforementioned are provided.01-21-2010
20080305500NOVEL CELL-BASED ASSAYS FOR IDENTIFYING ENHANCERS OR INHIBITORS OF T1R TASTE RECEPTORS (T1R2/T1R3 SWEET) AND UMAMI (T1R1/T1R3 UMAMI) TASTE RECEPTORS - This invention relates to improved assays for identifying modulators (enhancers or inhibitors) of sweet (T1R2/T1R3) and umami (T1R1/T1R3) taste receptors. These receptors may comprise the endogenous T1Rs e.g., from humans or rodents, or may comprise functional variants such as chimeric taste receptors comprising the extracellular portion of one T1R or a variant or fragment thereof, either T1R1 or T1R2, and the transmembrane portion of another T1R or a variant or fragment thereof, either T1R1 or T1R2, preferably associated with a T1R3 polypeptide and a suitable G protein. The subject assays preferably use endogenous taste or gastrointestinal cells which express T1R taste receptors or recombinant cell which express such T1Rs, for example mammalian cells or 12-11-2008
20110306064Quantifiable Internal Reference Standards For Immunohistochemistry And Uses Thereof - Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC.12-15-2011
20110306063METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Clusterin, Heart-type fatty acid binding protein, Hepatocyte growth factor, Interferon gamma, Interleukin-12 subunit beta, Interleukin-16, Interleukin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9, Midkine, and Serum amyloid P-component as diagnostic and prognostic biomarkers in renal injuries.12-15-2011
20100178658SCREENING ASSAYS FOR INHIBITORS OF BETA AMYLOID PEPTIDE ION CHANNEL FORMATION - Screening assays and methods of employing the screening assays designed to identify potential inhibitors of amyloidal neurodegenerative disease. The screening assays comprises providing a membrane construct disposed on a substrate and contacting the membrane construct with Aβ peptide capable of forming an Aβ peptide ion channel in the construct. The membrane construct is then contacted with a test compound. Aβ peptide ion channel activity is determined after the construct has incubated with the Aβ peptide in the presence and in the absence of the test compound. A reduction in the Aβ peptide ion channel activity of the membrane construct contacted with the test compound in comparison to a different membrane construct contacted with the same Aβ peptide in the absence of said test compound indicates that the test compound is an inhibitor of amyloidal neurodegenerative disease.07-15-2010
20090068683MARKERS FOR PREECLAMPSIA - This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided.03-12-2009
20100035279Fluorescent Substrates for Monoamine Transporters as Optical False Neurotransmitters - The present invention relates to compounds of the general structure: wherein Y is O, X is O, bond α is absent and bond β is present, or Y is H, X is CH, bond α is present, and bond β is absent; atom Z is a carbon and bonds χ, δ and γ are present, or is a nitrogen and bonds χ, δ and γ are absent; R02-11-2010
20090011437Methods of Detecting Antibodies Specific for Denatured HLA Antigens - The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.01-08-2009
20100173332 Method for the Fluorescent Detection of Nitroreductase Activity Using Nitro-Substituted Aromatic Compounds - A method utilising one or more fluorogenic probes, for the detection of nitroreductase activity. The non-fluorescent probes are reduced in the presence of nitroreductase to form fluorescent derivatives that may be detected using fluorescence spectroscopy. In particular, the method may be used to detect and/or identify a plurality of nitroreductase in a single test environment07-08-2010
20100167315METHOD FOR INVESTIGATING THE RESPONSE TO A TREATMENT WITH A MONOCLONAL ANTIBODY - The invention relates to steps for the development or the quality control of recombinant monoclonal antibodies (MoAbr) used as medicaments, and also to the selection of the patients liable to effectively respond to a treatment with a given monoclonal antibody. More specifically, the invention relates to a method for evaluating, in vitro, the effector functions of NK cells in response to a test monoclonal antibody, comprising at least the following steps: (i) the NK cells are brought into contact with said monoclonal antibody, which is fixed on a support, in the presence of an agent for inhibiting the secretion of cytokines by said cells; (ii) by way of positive control for the activation of the NK cells, the same experiment is carried out using, in place of the test monoclonal antibody, a monoclonal antibody directed against the Fc RIIIa receptor; (iii) after an incubation period of at least 1 hour, the response of the NK cells is observed by measuring the presence of the CD107 marker at the cell surface, and also the presence of intracellular IFN and/or of intracellular TNF.07-01-2010
20090117594METHOD FOR MEASURING HUMAN MEGALIN - This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.05-07-2009
20120309028IMMUNOASSAY STANDARDS AND MEASUREMENT OF CLINICAL BIOMARKERS USING INTRA-ASSAY CALIBRATION STANDARDS - The present invention provides novel compositions and methods for creating quantitative standards to calibrate analytes. These compositions and methods enable the creation of standards and calibrators for analyzing analytes and measuring clinical biomarkers. Also provided are kits comprising the novel compositions for use in assays, for example sandwich immunoassays.12-06-2012
20110318756SMALL SPECIMEN STAINING AND DIAGNOSING OF CELLS - An immunohistochemical staining of small specimen comprises using a plurality of antibodies and/or antigens to mark certain cells with particular colors of stains in order to distinguish target cells, such as carcinoma cells, in a stained small specimen. For example, antibodies CD44, cytokeratin 20 and p53 may be used for selectively staining a specimen of a urothelial mucosal biopsy on a single slide. Mouse monoclonal antibody CD44 is associated only with reactive urothelial cells, while rabbit monoclonal antibody p53 is associated only with carcinoma cells. Mouse monoclonal antibody cytokeratin 20 is associated with both “umbrella cells” and carcinoma cells, but antibody p53 is not associated with umbrella cells, which are the most superficial urothelial cells and are characterized morphologically from the other cells in a prepared specimen. Thus, diagnosis is facilitated by the staining of carcinoma cells in a contrasting color to normal urothelial cells and superficial urothelial cells.12-29-2011
20120208211HUMANISED PSORIASIS MODEL - The present invention relates to a new humanised animal model of psoriasis. Said model is generated by grafting humanised skin equivalents in the animal, injecting T lymphocytes and cytokines involved in the generation of the disease in humans, and performing the tape-stripping technique in order to generate damage in said grafted equivalents. Said model may be used to study the disease, as well as for the identification and evaluation of the efficacy of compounds against said disease.08-16-2012
20090305307Methods for detecting targets - The present invention provides method and compositions for detecting target molecules present on cells and tissues. In particular, the methods involve adding primary antibodies such as scFv-targeted lactamase that are directed against a target of interest (e.g., cancer markers) to a tissue sample, followed by adding a lactam-containing compound and finally a lactamase reporter system. In some preferred embodiments, the lactamase reporters are fluorescent reporters that bind to the test tissue. In some particularly preferred embodiments, the test tissue contains at least once cancer cell and/or at least one cancer-associated marker.12-10-2009
20120045777NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC, DIAGNOSTIC, PREVENTIVE, THERAPEUTIC, AND OTHER USES - The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.02-23-2012
20100216165USE OF SOLUBLE FORMS OF THE DESMOGLEIN I PROTEIN FOR THE PURPOSES OF SCREENING FOR ANTI-AGEING ACTIVE AGENTS - The invention relates to the use of one or more complexed or noncomplexed, soluble peptide form(s) of Desmoglein I, as a marker for evaluating the effectiveness of active agents and/or of treatments, in particular anti-ageing active agents and/or treatments, with regard to an epidermis.08-26-2010
20120003670Methods and Kits for Measuring Von Willebrand Factor - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor.01-05-2012
20120208210Post-Translational Modifications Indentified by Elemental Analysis - Methods and kits for enzymes involved in post-translational modifications are provided. The methods employ elemental analysis, including ICP-MS. The methods allow for the convenient and accurate analysis of post-translation modifications of substrates by enzymes involved in post-translational modifications, including kinase and phosphatase enyzmes08-16-2012
20120009598T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.01-12-2012
20120009601METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS - The present invention is directed, in part, to methods and compositions comprising inhibitors of micro RNA-145 and activators of the TGF-β signaling pathway to permit reprogramming using only small molecule compounds. Also described herein are methods to distinguish cancer cells or cells having cancerous potential in human iPS cell populations, based on determining the balance of p21-p53 expression levels, or ratio thereof in reprogrammed cells. In further aspects, methods and compositions to cause redifferentiation of a hepatoma cell to a hepatocye-like cell using acyclic retinoid and inhibitors of AKR1B10 are provided.01-12-2012
20120009600METHOD OF DIAGNOSING ADOLESCENT IDIOPATHIC SCOLIOSIS - A method for diagnosing an increased risk for developing adolescent idiopathic scoliosis (AIS) in a human subject, comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in a cell sample of the subject in the presence and in the absence of a known melatonin-signaling pathway agonist, wherein the cell sample is selected from the group consisting of blood cell sample, osteoblast cell sample, osteoclast cell sample and myoblast cell sample, and wherein the presence of the at least one impairment in the melatonin-signaling pathway indicates that the subject possesses an increased risk for developing AIS.01-12-2012
20120009597Biomarker for Barrett's Oesophagus - The present invention relates to the use of TFF3 in the diagnosis and detection of Barrett's Oesophagus using non-invasive, non-endoscopic methods.01-12-2012
20120009596PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.01-12-2012
20120009599METHOD FOR DETECTING MEMBRANE PROTEIN INTERNALIZATION - A method for detecting the internalization of a transmembrane protein of interest expressed at the surface of a cell, comprising the following steps: 01-12-2012
20090215084B7-H1 AND B7-H4 IN CANCER - Methods of determining prognosis of a subject with cancer or determining risk of cancer progression by assessing expression of B7-H4, or B7-H1 and B7-H4 in combination.08-27-2009
20110165595APPARATUS AND METHODS FOR PROCESSING A WHOLE BLOOD SAMPLE - The present invention provides a device and method for heating a whole blood sample for use in an assay, comprising irradiating said whole blood sample with monochromatic visible light of between 380 nm and 740 nm to raise the temperature of said whole blood sample to a target temperature between about 35° C. and 40 ° C. An apparatus for heating whole blood samples stored in a cartridge is further described comprising a housing assembly disposed to receive the cartridge one or more visible light optical emitters disposed in the housing apparatus and configured to selectively illuminate a staging area of the cartridge a temperature sensor disposed in the housing apparatus and configured to sense a temperature of the cartridge and a control circuit coupled to the temperature sensor and the array of visible light optical emitters so as to control a heating profile of the whole blood sample.07-07-2011
201001840974,5-BIS(4-METHOXYPHENYL)IMIDAZOLE COMPOUND INDUCING DIFFERENTIATION OF MYOBLASTS OR MUSCLE FIBERS INTO NEURON CELLS, A PHARMACEUTICAL COMPOSITION INCLUDING SAID COMPOUND, A METHOD OF INDUCING NEURON CELLS DIFFERENTIATION AND A SCREENING METHOD FOR IDENTIFYING ADDITIONAL COMPOUND USEFUL FOR INDUCING NEURON CELLS DIFFERENTIATION - The present invention relates to 4,5-bis(4-methoxyphenyl)imidazole compound inducing differentiation of myoblasts or muscle fibers into neuron cells, a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation. More specifically, it relates to 2-{2-[5-(3-chlorophenyl)]furanyl}-4,5-bis(4-methoxyphenyl)imidazole that induces differentiation of myoblasts or muscle fibers into neuron cells, all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug thereof, and a pharmaceutical composition including said compound, a method of inducing neuron cells differentiation and a screening method for identifying additional compound useful for inducing neuron cells differentiation.07-22-2010
20120058491METHOD FOR INDUCTION OF DIFFERENTIATION OF ES CELL - It is an object of the present invention to establish a system for reliably differentiating an ES cell into a hepatic cell. The present invention provides a method for inducing the differentiation of an ES cell into a hepatic cell, which comprises, in the presence of an M15 cell, culturing a mammal-derived ES cell in the presence of activin and bFGF, and then culturing the ES cell in the presence of dexamethasone, HGF, and oncostatin M.03-08-2012
20120064545MOUSE MODEL FOR POMPE DISEASE AND METHODS OF USE THEREOF - The present invention provides mouse models for Pompe disease and methods of using the same to test agents that may be effective in the treatment of Pompe disease.03-15-2012
20120156697Method for Identifying an Agent that Inhibits Candida albicans-Mediated Host Cell Differentiation - The present invention features a method for identifying an agent that inhibits 06-21-2012
20120156696 container for forming a cell aggregate and a method for forming a cell aggregate - A container for forming a cell aggregate is provided in which a group represented by a general formula of:06-21-2012
20120156695MICROORGANISM FOR EXPRESSING A HUMAN MEMBRANE PROTEIN - The invention relates to an isolated, genetically modified, living non-mammal organism, having increased HMG-CoA-reductase activity compared to the wild type, and having reduced C24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type. The invention further relates to different uses of such an organism, to a test kit comprising such an organism, and to a membrane extract of such an organism.06-21-2012
20120070847Method For Detecting And Purifying Pancreatic Beta Cells - The invention is based, in part, on the discovery that a polypeptide, referred to herein as Betacam, is selectively expressed on the surface of pancreatic islet cells, Thus, in one aspect, the invention is directed to compositions comprising Betacam or that can be used to detect Betacam. In another aspect, the invention provides methods of detecting (e.g., non-invasively) pancreatic beta cells from a mammalian cell source. Another aspect of the invention is directed to cellular purification of pancreatic beta cells from a heterogeneous cell source of multiple kinds. In another aspect, the invention provides methods of identifying agents that modulate activity of Betacam-In yet another aspect, the invention provides for improved treatment and diagnosis of diabetes.03-22-2012
20120070846METHODS FOR DETECTING MOLECULE-MOLECULE INTERACTIONS WITH A SINGLE DETECTION CHANNEL - A single molecule or molecule complex detection method is disclosed in certain aspects, comprising nano- or micro-fluidic channels.03-22-2012
20090325198Non-Denaturing Lysis Reagent For Use With Capture-In-Solution Immunoassay - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and non-specific animal immunoglobulins. Other aspects of the invention include related immunoassays and test kits.12-31-2009
20100047827NOVEL SPECIFIC CELL BINDERS - The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.02-25-2010
20100216164MAMMALIAN PRICKLE GENE - The present invention provides the mPrickle gene which encodes a protein present in mammalian PSD fractions. The mPrickle protein is localized in synapses, and binds to the scaffold protein PSD-95. Precipitation of endogenous mPrickle using an anti-mPrickle antibody results in the coprecipitation of NMDA receptors, and thus, mPrickle can be used in drug delivery systems that target NMDA receptors. NMDA receptors are closely related to learning and memory, and are also suggested to be involved in mental disorders. Thus, in the future, mPrickle is expected to be applicable to the diagnosis and/or treatment of neurodegenerative diseases associated with learning/memory, such as mental deterioration and dementia.08-26-2010
20090142780METHODS OF DONOR SPECIFIC CROSSMATCHING - The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating endothelial cell antibodies and methods for donor-specific crossmatching.06-04-2009
20090087866HUMAN T2R RECEPTORS FOR RANITIDINE, STRYCHNINE AND DENATONIUM AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter ligands, i.e., acetaminophen, ranitidine, strychnine and denatonium. The present invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors and which may be used as additives in foods, beverages and medicinals for modifying (blocking) T2R-associated bitter taste.04-02-2009
20120231477Blood Biomarkers for Bone Fracture and Cartilage Injury - Blood biomarkers are described for use in methods and compositions to determine whether an individual has sustained a bone fracture or a cartilage injury.09-13-2012
20110104716NOVEL METHOD FOR SCREENING BRAIN-ACTIVE COMPOUNDS - The invention relates to a novel screening method for brain-active substances and mixtures using hippocampal slices.05-05-2011
20120135423Methods for GPCR signaling pathway determination using biosensor-cell assays - A system and method for GPCR signaling pathway analysis and elucidation using a biosensor, a live-cell, and a pathway active compound, as defined herein.05-31-2012
20120122119METHODS OF IDENTIFYING COMPOUNDS THAT BIND TO A TOLL-LIKE RECEPTOR - The present invention is directed to nucleic acid molecules and polypeptides encoding a dsRNA receptor (dsRNA-R). The dsRNA-R contains a THD, interacts with the MyD88 adapter protein, and may bind to dsRNA. The present invention is also directed to antibodies against dsRNA-R and to methods of modulating an immune response and the methods of identifying compounds which bind to and/or modulate dsRNA-R.05-17-2012
20100143946ALPHA-SYNUCLEIN KINASE - The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.06-10-2010
20090130692Use of microproteins as tryptase - Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses.05-21-2009
20110183359METHODS FOR DETECTING MODULATORS OF CYTOKINE RECEPTOR ZALPHA11 - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zalpha11, a novel cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zalpha11, are located on chromosome 16, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.07-28-2011
20120129189Methods of Controlling Cell Proliferation - The present disclosure provides methods for increasing self-renewal/expansion of stem cells. The present disclosure provides methods of reducing uncontrolled cell proliferation. The present disclosure provides methods of identifying agents that modulate Notch1/-catenin binding, and methods of identifying agents that inhibit enzyme-mediated cleavage of Notch1 intracellular domain from Notch1 transmembrane domain.05-24-2012
20120164664T1R TASTE RECEPTORS AND GENES ENCODING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.06-28-2012
20100081150Methods for Generating Host Cells - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.04-01-2010
20120315652SWEET TASTE RECEPTOR-EXPRESSING CONSTRUCT, CELL BODY EXPRESSING THE SAME, AND UTILIZATION THEREOF - [Object] An object of the present invention is to provide a sweet taste receptor-expressing construct which can functionally stably express both of a sweet taste receptor (T1R2+T1R3) and a G protein α subunit at a high expression efficacy, and a stable expression cell body expressing the construct.12-13-2012
20120315651COMPOSITIONS AND METHODS FOR AUTOLOGOUS GERMLINE MITOCHONDRIAL ENERGY TRANSFER - Oogonial stem cell (OSC)-derived compositions, such as nuclear free cytoplasm or isolated mitochondria, and uses of OSC-derived compositions in autologous fertility-enhancing procedures are described.12-13-2012
20120219969MARKER FOR NEUROMYELITIS OPTICA - The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).08-30-2012
20120171699ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEXES IN FFPE MATERIAL - The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.07-05-2012
20120252037STIMULATORY AUTO-ANTIBODIES TO THE PDGF RECEPTOR AS PATHOLOGY MARKER AND THERAPEUTIC TARGET - An in vitro method for detecting the presence in a body sample of auto-antibodies for the PDGF receptor suitable for the diagnosis and prognosis of autoimmune diseases, in particular the systemic sclerosis and related diagnostic kits. Use of an inhibitor of ROS and/or Ras-ERK1/2 for the preparation of a medicament for therapeutic treatment of autoimmune diseases or of treating the Graft-Versus-Host-Reaction (GVHR). Pharmaceutical composition comprising an effective amount of an inhibitor of ROS and/or Ras-ERK1/2, and proper diluents, and/or excipients, and/or adjuvants.10-04-2012
20120077211STABLE COMPOSITIONS COMPRISING CHROMOGENIC COMPOUNDS AND METHODS OF USE - Compositions, assays, methods, and kits are disclosed for use in applications that utilize oxidation of a chromogenic electron donor such as diaminobenzidine (DAB) to generate a signal. Applications include, but are not limited to, immunohistochemistry, chromogenic in situ hybridization, Western blots, Northern blots, Southern blots, ELISA assays, and microarray detection. The compositions, assays, methods, and kits disclosed herein make use of a novel, stabilized formulation of DAB and a novel, stabilized formulation of hydrogen peroxide.03-29-2012
20100047826Cell Into Which Protein, Which Can Serve as Polymerization Nucleus of Protein Polymer, or Polymer Thereof Is Introduced, and Method for Production of The Cell - The present invention has the object of providing a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or polymer thereof is introduced, and a method for producing the cell. The invention relates to a cell into which a protein, which can serve as a polymerization nucleus of a protein polymer, or a polymer thereof is introduced, a method for producing the cell, and a method of screening for a compound inhibiting an intracellular accumulation of a protein containing fibril structures, wherein the method comprises bringing a candidate substance into contact with the cell.02-25-2010
20120219968GPCR Expressing Cell Lines and Antibodies - The present invention provides expression vectors that facilitate high levels of expression of GPCR proteins. Encompassed by the invention are methods and compositions for recombinant cell lines expressing GPCR proteins with the aid of the expression vectors of the instant invention. The recombinant cell lines of the instant invention express GPCR proteins at levels of at least about 150,000 copies of the protein per cell. The present invention also provides methods and compositions for raising antibodies against GPCR proteins using the high expressing recombinant cells of the instant invention.08-30-2012
20120219967CHOLINERGIC/SEROTONINERGIC RECEPTOR AND USES THEREOF - The present invention describes new cholinergic/serotoninergic chimeric receptors and provides methods and compositions suitable for screening for ligands such as agonists, antagonists and allosteric modulators of α7 nicotinic acetylcholine receptors.08-30-2012
20120178103DETECTION OF DYSPLASTIC OR NEOPLASTIC CELLS USING ANTI-MCM6 ANTIBODIES - Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.07-12-2012
20100035280Chimeric Fc-gamma Receptor and Method for Determination of ADCC Activity by Using the Receptor - An objective of the present invention is to provide chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human Fcγ receptor transmembrane domain, or chimeric receptors containing a mouse Fcγ receptor extracellular domain and a human γ chain transmembrane domain. Another objective of the present invention is to provide methods for measuring the ADCC activity of mouse antibodies and methods of screening for mouse antibodies having ADCC activity, using the chimeric receptors.02-11-2010
20090061462Prion-specific peptide reagents - Peptide reagents that interact preferentially with the PrP03-05-2009
20090061461Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Therapeutic Target - A method of diagnosing diseases associated with aberrant biological phenotypes including contacting a sample to be tested with at least one isoform of membrane associated progesterone receptor component 1 (mPR) as a diagnostic marker, and determining or estimating the degree of phosphorylation of the membrane associated progresterone receptor component 1 (mPR).03-05-2009
20090317831Sepsis Test - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection.12-24-2009
20120258474METHODS OF DETECTING DNA DAMAGE - The present invention relates to methods of detecting agents that cause or may potentiate DNA damage, and to assays that may be employed in such methods. In particular, the invention relates to methods of detecting DNA damage in in vitro cultures of human cells.10-11-2012
20120083004Diagnostic Method for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue.04-05-2012
20120083002Methods For Modulating The Development Of Dopamine Neuron By The Dopamine D2 Receptor And Compositions Thereof - The present invention relates to a composition for modulating the activation of Nurr1, the composition comprising an agonist or an antagonist of a dopamine D2 receptor, methods for modulating the activation of Nurr1 by the dopamine D2 receptor, a method and composition for treating Nurr1-related diseases using the dopamine D2 receptor, and methods for screening a modulator of a dopamine D2 receptor of a test compound. Accordingly, the activation of Nurr1 can be modulated by treating the dopaminergic neurons with the agonist or the antagonist of the dopamine D2 receptor, thereby enhancing or inhibiting generation of the dopaminergic neurons.04-05-2012
20120083001METHOD FOR TRANSPORTING POTASSIUM IONS FROM FRONT SIDE TO BACK SIDE OF LIPID BILAYER MEMBRANE - An object of the present invention is to detect a specific chemical substance with high sensitivity and high precision. By using a specific lipid bilayer membrane, a chemical substance is detected with high sensitivity and high precision. Here, the specific lipid bilayer membrane comprises a chemical substance receptor, a chimeric G protein, and a potassium ion channel. The chimeric G protein comprises a chimeric G04-05-2012
20120083000Neuropeptide Release Assay For Sodium Channels - Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a Na04-05-2012
20120190048METHOD FOR DETERMINING THE BINDING OF A GIVEN COMPOUND TO A MEMBRANE RECEPTOR - The invention relates to a method for determining whether a test compound binds preferentially to a membrane receptor R1 or to a membrane receptor R2, these receptors being known to be expressed on the surface of the cells in monomeric, homodimeric or heterodimeric form. This method is applied using one or two FRET partner pairs.07-26-2012
20080299587METHODS OF MEASURING INHIBITION OF PLATELET AGGREGATION BY THROMBIN RECEPTOR ANTAGONISTS - A method is provided for measuring inhibition of platelet aggregation by a thrombin receptor antagonist. First, a blood sample is obtained from a patient treated with a thrombin receptor antagonist. The blood sample is mixed in combination with particles including an immobilized GPIIb/IIIa receptor ligand and a thrombin receptor activator. The combination is then incubated under conditions suitable for agglutinating the particles, and platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi in response to the thrombin receptor antagonist treatment. Also provided is a kit for measuring inhibition of platelet aggregation by a thrombin receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, a thrombin receptor activator, an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.12-04-2008
20080299586OLFACTORY RECEPTORS FOR ISOLVALERIC ACID AND RELATED MALODORANTS AND USE THEREOF IN ASSAYS FOR IDENTIFICATION OF BLOCKERS - A subgenus of olfactory receptors (ORs) that are activated by isovaleric acid (IVA) are identified as well as assays that utilize one or more of these ORs. These assays are useful for identifying potential anti-odorants which may be used in deodorants, air and carpet fresheners, fabric deodorizers, and other compositions for camouflaging odor attributable to IVA and related carboxylic acids.12-04-2008
20080299588Methods For Measuring Bone Formation - The present invention relates to methods for detecting and monitoring bone mineralization. The invention provides antibodies, kits, and methods of use for detecting or monitoring the rate of bone mineralization associated with bone disorders such as osteoporosis.12-04-2008
20110003318NUCLEOTIDE AND PROTEIN SEQUENCE OF MAMMASTATIN AND METHODS OF USE - A nucleic acid sequence encoding Mammastatin, a specific mammary cell growth inhibitor. Mammastatin is encoded by a single nucleic acid sequence and has an approximate molecular weight of 44 kDa in its inactive, non-phosphorylated form. Normal mammary cells express functional phosphorylated forms having approximate molecular weights of 53 kDa and 49 kDa. Metastatic mammary cells either do not express Mammastatin at all, or do not express the 53 kDa or 49 kDa, phosphorylated forms. Mammary cancer cells are inhibited in their growth by the administration of phosphorylated mammastatin.01-06-2011
20110003317METHODS OF SCREENING COMPOUNDS FOR INSECT-CONTROL ACTIVITY INVOLVING THE TYRAMINE RECEPTOR - An exemplary method of screening compositions for insect control activity includes, providing an insect cell expressing a receptor of the insect olfactory cascade or fragment thereof, contacting a test composition to the insect cell, measuring at least one parameter selected from olfactory cascade receptor binding affinity, intracellular cAMP levels, and intracellular Ca01-06-2011
20110003316LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY - The present invention provides methods, compositions, substrates, and kits useful for analyzing the metabolic activity in cells, tissue, and animals and for screening test compounds for their effect on cytochrome P450 activity. In particular, a one-step and two-step methods using luminogenic molecules, e.g. luciferin or coelenterazines, that are cytochrome P450 substrates and that are also bioluminescent enzyme, e.g., luciferase, pro-substrates are provided. Upon addition of the luciferin derivative or other luminogenic molecule into a P450 reaction, the P450 enzyme metabolizes the molecule into a bioluminescent enzyme substrate, e.g., luciferin and/or luciferin derivative metabolite, in a P450 reaction. The resulting metabolite(s) serves as a substrate of the bioluminescent enzyme, e.g., luciferase, in a second light-generating reaction. Luminescent cytochrome P450 assays with low background signals and high sensitivity are disclosed and isoform selectivity is demonstrated. The present invention also provides an improved method for performing luciferase reactions which employs added pyrophosphatase to remove inorganic pyrophosphate, a luciferase inhibitor which may be present in the reaction mixture as a contaminant or may be generated during the reaction. The present method further provides a method for stabilizing and prolonging the luminescent signal in a luciferase-based assay using luciferase stabilizing agents such as reversible luciferase inhibitors.01-06-2011
20110003315CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.01-06-2011
20100143945DNA-DAMAGE-INDUCED PROTEOLYSIS - The present application provides methods for identifying compounds for inhibiting DNA damage-induced Htt proteolysis, and methods and compositions for protecting cells from DNA damage-induced cleavage of Htt.06-10-2010
20120322084CELL LINES COMPRISING SOUR-TASTE RECEPTORS - The present invention relates to sour taste receptors and compositions and methods thereof. In particular, the present invention provides assays and methods of screening for ligands specific for sour taste receptors. Additionally, the present invention provides methods for screening for accessory proteins and mutations, polymorphisms and other potential sour taste receptor protein mutations that are associated with disease states, and therapeutic agents, ligands, and modulators of such proteins. The present invention also provides compositions and methods for modulating sour taste receptors in vitro and in vivo.12-20-2012
20120322083ANTIBODY BINDING TO ABCA1 POLYPEPTIDE - The invention relates to an isolated antibody that binds to native ABCA1 polypeptide and its uses for the detection of ABCA1 polypeptides in tissue samples.12-20-2012
20090220999Antibodies immunoreactive with mutant 5-enolpyruvlshikimate-3-phosphate synthase - Antibodies immunoreactive to double mutant EPSPS are provided, and in an embodiment the double mutant EPSPS is one in which the wild-type EPSPS is substituted at residue 102 with isoleucine and at residue 106 with serine. Also provided are hybridomas producing the antibodies, as well as methods of making and using the antibodies.09-03-2009
20110045500CELL CULTURE METHOD AND SCREENING METHOD - Provided is a cell culture method whereby an in vivo function can be sustained over a long period of time and culture can be conducted using the minimum number of cells required. The cell culture method includes culturing undifferentiated cells in a layered state in a partitioned micro-space and obtains differentiated cells. When screening a pharmaceutical agent, undifferentiated cells capable of differentiating into liver cells, intestinal epithelial cells, nerve cells, myocardial cells and vascular endothelial cells are preferred. Particularly, in the prediction of pharmacokinetics or the like for humans, human cells are preferred.02-24-2011
20110045499Screening systems utilizing RTP801 - RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801.02-24-2011
20110045498On-Site Liquid Production - A biological sample processing system for on-site liquid production comprises a processing apparatus for processing of biological samples arranged on microscope slides, and a production unit connected to the apparatus. The production unit comprises a first ingredient source, a second ingredient source, and a mixer station. The mixer station is configured to mix ingredients to produce a liquid product. Supply conduits are arranged to supply an amount of a first ingredient and an amount of a second ingredient from the first and second ingredient sources to the mixer station. A delivery conduit is provided for transportation of an amount of the liquid product from the mixer station. A production controller is arranged in communication with the production unit, and is configured to control the operation of the production unit.02-24-2011
20110045497NOVEL ACIDIC GLYCAN MARKERS OF HUMAN CELLS - The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules.02-24-2011
20110045496GAL ALPHA 1-3GAL-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS DERIVED FROM CHO CELLS - The present invention provides methods of evaluating CHO cells.02-24-2011
20100203556METHODS OF USING A G PROTEIN-COUPLED RECEPTOR TO IDENTIFY PEPTIDE YY (PYY) SECRETAGOGUES AND COMPOUNDS USEFUL IN THE TREATMENT OF CONDITIONS MODULATED BY PYY - The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.08-12-2010
20110236909LASER SCANNING CYTOMETRY MEDIATED ANALYSIS OF THERAPEUTIC EFFICACY IN TUMORS - This invention describes the use of a laser scanning device, for example a laser scanning CYTOMETRY (LSC), with a double-fluorescent labeling technique as a quantitative method that can be used to objectively and accurately measure endothelial cell death, endothelial tumor cell death and blood vessel density of tumor tissue. These parameters can be used as markers of efficacy in tumors treated with anti-angiogenic or traditional therapies and can distinguish patients who respond to these drugs from those who do not.09-29-2011
20100233730THERAPEUTIC MODULATION OF AUTOPHAGY - Methods for screening for modulators of autophagy are disclosed. Methods for identifying genes whose expression inhibits autophagy, as well as genes whose expression promotes autophagy, are disclosed. Also disclosed are methods for identifying compounds that stimulate autophagy, as well as compounds that inhibit autophagy. Cell lines that may be used in the methods of identification are also disclosed.09-16-2010
20120276553MESENCHYMAL PRECURSOR CELL - A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.11-01-2012
20110262937T1R HETERO-OLIGOMERIC TASTE RECEPTORS AND CELL LINES THAT EXPRESS SAID RECEPTORS AND USE THEREOF FOR IDENTIFICATION OF TASTE COMPOUNDS - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners.10-27-2011
20100184095Steroid Hormone Assay Method - The level of a steroid hormone, including estrogen, in the stratum corneum of the skin is assayed by LC-MS analysis of a steroid hormone in the stratum corneum of the skin collected by a tape stripping method. This allows the concentration in the skin of the steroid hormone, including estrogen which has an important effect on the state of the skin, to be easily measured.07-22-2010
20120329075MONITORING PROTEIN TRAFFICKING USING BETA-GALACTOSIDASE REPORTER FRAGMENT COMPLEMENTATON - Methods and materials are disclosed for use in an enzyme fragment complementation assay using complementary fragments of β-galactosidase to study the trafficking of proteins in a cell. Compounds that bind to a target peptide have been found to affect protein folding and therefore trafficking. β-Galactosidase fragments, an enzyme donor (ED) and an enzyme acceptor (EA), are fused to a target peptide and to an intracellular compartment protein, wherein the compartment is involved in intracellular trafficking. Contacting the cell with a compound that binds to the target peptide results in enhanced movement of the protein through the cellular trafficking pathway comprised of the endoplasmic reticulum, Golgi apparatus, the plasma membrane, endosomes, etc. Using this approach, compounds that bind to a target peptide and alter its ability to traffic through the normal cellular pathway can be readily detected.12-27-2012
20120100559NOVEL HYDROPHILIC AND LIPOPHILIC RHODAMINES FOR LABELLING AND IMAGING - The invention relates to novel and improved photostable rhodamine dyes of the general structural formulae I or II and their uses as fluorescent markers, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional and stimulated emission depletion (STED) microscopy and fluorescence correlation spectroscopy. The partially deuterated analogues are useful as molecular mass distribution tags in mass spectroscopic applications. wherein R04-26-2012
20090104630Semi-quantitative immunochromatographic device and method for the determination of HIV/AIDS immune-status via measurement of soluble CD40 ligand/CD 154, A CD4+T cell equivalent - A semi-quantitative, immunochromatographic device for the detection of HIV/AIDS immune status CD4+ T cell equivalents, such as soluble CD40 ligand/CD 154, includes one or more support materials capable of providing lateral flow. The one or more support materials include a first area for receiving a biological sample containing a target analyte, the analyte being a CD4+ T cell equivalent, such as soluble CD40 ligand/CD 154, a second area having a movably contained detector ligand, wherein the detector ligand is capable of forming a mobile complex with the soluble CD40 ligand/CD 154, and at least one capture area having a predetermined amount of an immobile capture reagent, the immobile capture reagent capable of specifically binding to the mobile complex formed by the soluble CD40 ligand/CD 154 protein and the detector ligand and providing a visible signal.04-23-2009
20100151499PROTEOLYTIC RELEASE OF GLYCANS - The present disclosure provides strategies for analyzing protein-linked glycans, and particularly for analyzing glycans on cell surface glycoproteins.06-17-2010
20100167314CONTROL OF INTRACELLULAR TARGET MOLECULE BY IP3 RECEPTOR-BINDING PROTEIN - The present invention provides a composition comprising an IP07-01-2010
20130011861MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1 - Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.01-10-2013
20100129833Methods to Identify Modulators - Sucralose-binding TAS2R bitter taste receptors have been identified. Novel methods to identify modulators and in particular inhibitors to the bitter taste of sucralose and an inhibitor, are provided.05-27-2010
20110136144FIBROBLAST GROWTH PATTERNS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE - Methods of diagnosing Alzheimer's disease are provided. At least five methods of diagnostic measurements are presented: Method 1: Integrated score; Method 2: Average aggregate area per number of aggregates; Method 3: Cell migration analysis; Method 4; Fractal analysis; Method 5: Lacunarity Analysis. In certain embodiments, a sample of a subject's skin provides a network of fibroblasts that is imaged and a fractal dimension of the image is calculated. The fractal dimension can be compared to an aged-matched control (non-Alzheimer's) database to determine if the subject has Alzheimer's disease. The network of fibroblasts may be cultured in a matrix, for example in a protein mixture.06-09-2011
20110159522Three-Dimensional Microfluidic Platforms and Methods of Use Thereof - Provided are methods and devices for formation and study of three-dimensional biological systems, including prokaryotic and eukaryotic cell migration, proliferation, and differentiation.06-30-2011
20080254487Connective Tissue Growth Factor Signaling - The present invention provides compounds and agents that modulate CTGF-mediated cell adhesion and/or binding of CTGF to cells. The invention further provides assays that may be used to identify additional modulators of CTGF-mediated cell adhesion and CTGF binding to cells, and assays that may be used to identify compounds or agents that modulate interaction of CTGF with HSPGs.10-16-2008
20080248496NUCLEAR MATRIX PROTEIN ALTERATIONS ASSOCIATED WITH COLON CANCER AND COLON METASTASIS TO THE LIVER, AND USES THEREOF - Proteins useful in the diagnosis of proliferative disorders of the colon are present in nuclear matrix protein preparations and can be characterized by molecular weight, isoelectric point, and amino acid sequence. The proteins may be identified, for example, by 2D-gel electrophoresis or by specific binding partners, such as antibodies.10-09-2008
20080248495Guinea pig proteinase-activated receptor 4 and its activating peptide - This invention relates to nucleic acid encoding guinea pig PAR 4 and to the protein encoded thereby. The guinea pig DNA and protein are useful for the development of models of human platelet aggregation. The invention further relates to an animal model to assess the role of PAR antagonists in thrombosis.10-09-2008
20080318251Mammalian Sweet And Amino Acid Heterodimeric Taste Receptors - The present invention provides isolated nucleic acid and amino acid sequences of sweet or amino acid taste receptors comprising two heterologous G-protein coupled receptor polypeptides from the T1R family of sensory G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of sweet and amino acid taste receptors.12-25-2008
20080233598Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer - A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P2A3 can be used in active or passive immunization.09-25-2008
20080227121Inducible ligand for alpha1beta1 integrin and uses - The present invention is directed to the identification and use of agents, particularly peptides and monoclonal antibodies that disrupt the interaction between Collagen XIII and α1β1 integrin.09-18-2008
20080227120FRET-BASED ASSAY FOR SCREENING MODULATORS OF RECEPTOR CYCLING - Automated FRET imaging of membrane-bound receptor/ligand complexes can discriminate between a clustered organization of ligand/receptor complexes that occurs during the early endocytic stages following internalization and a random distribution characteristic of late stage disassociation of ligand from the receptor. In the case of the low density lipoprotein receptor (LDL-R) and its ligand, LDL, this feature of FRET imaging forms the basis of an assay to monitor the endosomal release of cholesterol into the cell and identify compounds which alter pH in the endosome thereby inhibiting the disassociation of ligand and cholesterol from the receptor, a mechanism that is involved in regulation of plasma/serum cholesterol.09-18-2008
20080227119ELISA for VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.09-18-2008
20080227118Protein Immobilization Method and Quantification Method - The present invention relates to a method for immobilizing a protein in a sample, which could not easily be immobilized by the conventional immobilization method, to a solid-phase; a method for quantitative determination of protein wherein an effect of inhibitory substance coexisting in a sample prepared using the immobilization method can be reduced; and a rapid and highly precise method for detecting an abnormal PrP and a method for determining BSE using the immobilization method as compared with the conventional method. The present invention provides: “a method for immobilizing a protein to a solid-phase comprising contacting the protein with the solid-phase having hydrophobic surface in the presence of a lower alcohol, and a halogenocarboxylic acid and/or a long chain alkyl sulfate, and an immobilizing reagent solution to be used therefor; a method for quantitative determination of protein comprising contacting a protein-staining solution with the solid-phase immobilized with a protein by the immobilization method, and determining a degree of color development generated thereby; an immunoblotting method wherein the solid-phase immobilized with a protein by the immobilization method is used; and a method for detecting an abnormal PrP a method for determining BSE by using the immobilization method.”09-18-2008
20130177926Simultaneous Assay of Target and Target-Drug Binding - Whole cell, simultaneous target and drug-target assay using differentially labeled antibodies and flow cytometry. First antibody binds to total target and second antibody binds to the drug binding site of the target, thus drug binding will competitively inhibit the second antibody allowing for a competitive inhibition assay of drug-target binding. The assay allows for whole cell analysis and even analysis of mixed populations of cells, yet provides detailed kinetic assessment of drug activity.07-11-2013
20080220452KIT FOR DETERMINING POLYSACCHARIDE-BINDING ABILITY OF MONONUCLEAR CELLS PRESENT IN PERIPHERAL BLOOD - A kit for the determination of the ability of a peripheral blood mononuclear cell to bind to a polysaccharide herein provided comprises a detection reagent comprising a fluorescence-labeled immunostimulant polysaccharide; and a reference reagent comprising a fluorescence-labeled material of a polysaccharide different from that used in the fluorescence-labeled immunostimulant polysaccharide, and/or an immunostimulant polysaccharide which is not labeled with any fluorescent material and whose polysaccharide moiety is identical to that included in the fluorescence-labeled immunostimulant polysaccharide. The use of this kit would permit the estimation of the polysaccharide-binding ability of a peripheral blood mononuclear cell in a higher precision of estimation.09-11-2008
20080220451T1R2 BINDING ASSAYS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular taste stimulus in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.09-11-2008
20080220450Population Based Prediction Methods for Immune Response Determinations and Methods for Verifying Immunological Response Data - The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.09-11-2008
20130171664PH-RESPONSIVE FLUORESCENT FALSE NEUROTRANSMITTERS AND THEIR USE - This invention relates to compounds having the following structure:07-04-2013
20130171665METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.07-04-2013
20130115623USE OF MARKERS OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS - The disclosure relates to methods of binding and identifying undifferentiated pluripotent stem cells and particularly, although not exclusively, to use of binding moieties which bind to PHB on the surface of undifferentiated pluripotent stem cells, such as PHB-binding peptides, and to methods for depleting undifferentiated stem cells from a sample.05-09-2013
20130115625NOVEL PROTEIN AND USE THEREOF - A protein being the following (A), (B), or (C): (A) a protein represented by the amino acid sequence of SEQ ID NO: 1; (B) a protein represented by an amino acid sequence in which one or a plurality of amino acid is substituted, deleted, inserted or added in the amino acid sequence of SEQ ID NO: 1, the protein having binding activity specific for a mixture of a sphingolipid and cholesterol; or (C) a protein represented by an amino acid sequence being at least 70% identical to the amino acid sequence of SEQ ID NO: 1.05-09-2013
20130115624Methods To Identify Modulators - Disclosed are compounds that activate the human G-protein coupled receptor TAS2R41, and methods of using these compounds for identifying compounds that modulate the response of the TAS2R41 receptor. Compounds identified as modulators of the response of the receptor TAS2R41 may be used to decrease or mask the bitter taste of foods or drugs.05-09-2013
20130102010T1R Hetero-Oligomeric Taste Receptors and Cell Lines That Express Said Receptors and Use Thereof for Identification of Taste Compounds - The present invention relates to the discovery that the T1R receptors assemble to form functional taste receptors. Particularly, it has been discovered that co-expression of T1R1 and T1R3 results in a taste receptor that responds to umami taste stimuli, including monosodium glutamate. Also, it has been discovered that co-expression of the T1R2 and T1R3 receptors results in a taste receptor that responds to sweet taste stimuli including naturally occurring and artificial sweeteners.04-25-2013
20130115627METHODS FOR IDENTIFYING CANDIDATE CYTOTOXIC ANTIBODY MOLECULES - The disclosure relates to methods for screening candidate antibody molecules which bind to podocalyxin-like protein (PODXL) and/or to undifferentiated pluripotent stem cells and particularly, although not exclusively, to methods for identifying candidate cytotoxic antibody molecules.05-09-2013
20130115626ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE - The invention provides anti-NRP1 antibodies and methods of using the same.05-09-2013
20130177925DETECTION OF ANTIGEN-SPECIFIC PERIPHERAL BLOOD MONONUCLEAR CELLS AND METHODS FOR DIAGNOSING IMMUNE DISORDERS - The present invention relates to a method for detecting the presence or the absence, and optionally quantifying and/or isolating, antigen-specific peripheral blood mononuclear cells. This method, which involves flow cytometry, is based on the use of a fluorescently-labeled antibody specifically recognizing peripheral blood mononuclear cells, and of fluorescently-labeled beads coated with at least one antigen that is specifically recognized by antigen-specific peripheral blood mononuclear cells. The method according to the invention is for example useful for diagnosing immune disorders such as transplant rejections and autoimmune disorders.07-11-2013
20130143235COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS - Compositions that include isolated, functionally active, recombinantly produced class I HLA trimolecular complexes that include epitopes unique to breast cancer cells are disclosed.06-06-2013
20100279316Antibodies to Phosphorylated IRAK4 - The present invention relates to antibodies that bind phosphorylated forms of IRAK4, methods of using such antibodies to detect IRAK4 biological activity, and methods for the detection, diagnosis, and prognostication of pathological conditions related to IRAK4 biological activity. ERAK4 is one member of a small family of highly conserved cytoplasmic signal transduction proteins characterized by the presence of an N-terminal “death domain” and a C-terminal serine-threonine kinase domain. IRAK4 functions in cytoplasmic signal transduction pathways by interacting with membrane spanning proteins which play, inter alia, critical roles in vertebrate immune system function.11-04-2010
20090311720METHODS OF MODULATING AND IDENTIFYING AGENTS THAT MODULATE INTRACELLULAR CALCIUM - Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.12-17-2009
20080199889Human orphan G protein-coupled receptors - The invention disclosed in this patent document relates to transmembrane receptors, more particularly to endogenous, human orphan G protein-coupled receptors.08-21-2008
20080199888Non-endogenous, constitutively activated versions of human G protein coupled receptor: FSHR - The invention disclosed in this patent document relates to transmembrane receptors, particularly to a human G protein-coupled receptor, more particularly to a follicle stimulating hormone receptor (FSHR), and most particularly to mutated (non-endogenous) versions of the human FSHR for evidence of constitutive activity.08-21-2008
20110223618ASSAYS USING CHIMERIC T1R POLYPEPTIDE - This invention relates to chimeric taste receptors comprising the extracellular portion of one T1R or a variant or fragment thereof, either T1R1 or T1R2, and the transmembrane portion of another T1R or a variant or fragment thereof, either T1R1 or T1R2, preferably associated with a T1R3 polypeptide and a suitable G protein. These chimeric taste receptors and cells which express such chimeric taste receptors are useful in assays for identifying sweet and umami ligands as well in assays for identifying sweet and umami enhancers. Additionally, these chimeric taste receptors and cells which express same can be used to map and determine where specific sweet and umami ligands interact with their respective receptors and to elucidate the mechanism of receptor activation.09-15-2011
20130149715G-PROTEIN-CONJUGATED RECEPTOR HAVING ALTERED LIGAND AFFINITY, AND USE THEREOF - A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified.06-13-2013
20130149716METHODS AND KITS FOR MEASURING VON WILLEBRAND FACTOR - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor.06-13-2013
20130149717METHODS AND COMPOSITIONS RELATED TO DOPAMINERGIC NEURONAL CELLS - A method of differentiation stem cells cells by contacting stem cells with a dopaminergic differentiation agent is provided in certain aspects. For example, the agent may comprise substituted benzoxazole. These methods and compositions may be used in toxicological screens, e.g., to evaluate the neurotoxicity of a test compound or treatment of neurological disorders.06-13-2013
20100028910ACTIVATED PROTEIN C VARIANTS WITH NORMAL CYTOPROTECTIVE ACTIVITY BUT REDUCED ANTICOAGULANT ACTIVITY - Variants (mutants) of recombinant activated protein C (APC) or recombinant protein C (prodrug, capable of being converted to APC) that have substantial reductions in anticoagulant activity but that retain normal levels of anti-apoptotic activity are provided. Two examples of such recombinant APC mutants are KKK191-193AAA-APC and RR229/230AA-APC. APC variants and prodrugs of the invention have the desirable property of being cytoprotective (anti-apoptotic effects), while having significantly reduced risk of bleeding. The invention also provides a method of using the APC variants or prodrugs of the invention to treat subjects who will benefit from APC's cytoprotective activities that are independent of APC's anticoagulant activity. These subjects include patients at risk of damage to blood vessels or tissue in various organs caused, at least in part, by apopotosis. At risk patients include, for example, those suffering (severe) sepsis, ischemia/reperfusion injury, ischemic stroke, acute myocardial infarction, acute or chronic neurodegenerative diseases, or those undergoing organ transplantation or chemotherapy, among other conditions. Methods of screening for variants of recombinant protein C or APC that are useful in accordance with the invention are also provided.02-04-2010
20110275096Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis - Methods, compositions and kits are provided for assessing angiogenesis through sensitive, direct detection of activation of endothelial cells at molecular levels. In general, activation of endothelial cells is detected by measuring the levels of cellular components and their protein complexes participating in a specific angiogenesis signaling pathway in endothelial cells. The methods can be used for assessing status of diseases associated with undesirable angiogenesis, such as the likelihood of developing the disease, presence or absence of the disease, prognosis of the disease and the likelihood of response or resistance to a particular anti-angiogenic therapy. The methods can also be used to guide the design of effective therapeutic regimens targeting a specific angiogenic signaling pathway, as well as in conjunction with therapeutic intervention of diseases or conditions associated with undesirable angiogenesis.11-10-2011
20100297674NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM - Cells and cell lines that express voltage-gated sodium ion channels (NaV) and methods for using the cells and cell lines are disclosed herein. The NaV-expressing cells and cell lines are useful in high throughput screening assays.11-25-2010
20100317035USE OF SPECIFIC T2R TASTE RECEPTORS TO IDENTIFY COMPOUNDS THAT BLOCK BITTER TASTE - Assays for identifying compounds that modulate, preferably inhibit bitter taste associated with the activation of hT2R4, hT2R44 and/or hT2R61 are provided. The compounds identified according to these assays should modulate, e.g., inhibit bitter taste associated with bitter tasting compounds including quinine, 6-nitrosaccharin, saccharin and/or denatonium. These compounds are useful additives for foods, beverages or medicinal preparations having a bitter taste.12-16-2010
20100317034PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.12-16-2010
20130157289IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR - Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.06-20-2013
20130122521DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing.05-16-2013
20130122522ASSESSING MAMMALS FOR VASCULAR DISEASES AND VALVULAR DISEASES - This document provides methods and materials related to assessing mammals for vascular disease. This document also provides methods and materials related to assessing mammals for valvular disease. For example, methods and materials for assessing mammals for vascular disease using elevated levels of endothelial progenitor cells expressing a bone-related polypeptide (e.g., an osteocalcin polypeptide) as markers are provided.05-16-2013
20130122520METHODS FOR PURIFYING ENDODERM AND PANCREATIC ENDODERM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS - The present disclosure relates to compositions and methods comprising cell surface markers for hES-derived cells, in particular, endoderm lineage cells including pancreatic endoderm-type cells, derived from hES cells.05-16-2013
20110311991Methods of Identifying Modulators of the Bitter Taste Receptor TAS2R44 - Steviol glycosides have been discovered to bind the bitter taste receptor TAS2R44. Novel methods of identifying modulators and in particular inhibitors to the bitter taste of steviol glycosides and an inhibitor of steviol glycosides are provided.12-22-2011
20130189710Method And Assay Kit For Detection Of Toxicity Induced By Pyrrolizidine Alkaloids - An antibody, which specifically recognizes adducts between pyrrole and cellular macromolecules. Such adducts are likely to occur in mammals suffering an incident of pyrrolizidine alkaloid poisoning. The antibody can be produced using a synthetic immunogen conjugated with a pyrrole as a hapten and it can be used, for example in an assay kit and/or by itself, as a novel means for detecting or diagnosing pyrrolizidine alkaloid poisoning both clinics and research laboratories.07-25-2013
20130189714METHOD FOR THE DETECTION AND/OR QUANTIFICATION OF THE INTERACTION OF PLATELETS WITH INTERACTION PARTNERS - The invention refers to methods for detecting and/or quantifying the interaction of platelets or platelet surface molecules with an interaction partner, methods for detecting and/or quantifying the capability of a test substance to modulate the interaction of platelets or platelet surface molecules with interaction partners and articles or manufacture.07-25-2013
20130189713PLATELET AGGREGATION ASSAYS - The present invention provides methods of determining platelet aggregation, methods of determining susceptibility to clotting upon administration of a CD40L-binding moiety, and kits related thereto.07-25-2013
20130189712T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.07-25-2013
20120015378IDENTIFICATION OF BITTER LIGANDS THAT SPECIFICALLY ACTIVATE HUMAN T2R RECEPTORS AND RELATED ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery that specific human taste receptors in the T2R taste receptor family respond to particular bitter compounds. The invention further relates to the use of these receptors in assays for identifying ligands that modulate the activation of these taste receptors by these bitter ligands and related compounds and which may be used as additives and/or removed from foods, beverages, cosmetics and medicinals in order to modify (block) T2R-associated bitter taste.01-19-2012
20120015377METHOD AND APPARATUS FOR MEASURING BIOGENOUS BIOLOGICALLY ACTIVE SUBSTANCE - Provided is an assay method and an assay device whereby assay time can be largely shortened in the case of detecting a physiologically active substance of biological origin. The aggregation start time of a liquid mixture of an assay sample with LAL is determined. From this aggregation start time, the physiologically active substance is detected or the concentration thereof is measured. The liquid mixture of the assay sample with LAL is stirred with, for example, a magnetic stirrer to form gel particles. Next, the scattered light intensity of laser light scattered by these gel particles is measured. Then, the frequency distribution of the scattered light intensity fluctuation is obtained. Based on the temporal change in the frequency distribution shape, the aggregation start time of the liquid mixture of the assay sample with LAL is determined.01-19-2012
20120021440METHODS FOR TESTING LIGAND BINDING TO G PROTEIN-COUPLED RECEPTORS - The present invention relates to methods for testing for the binding of a ligand to a G Protein-Coupled Receptor. In particular, the methods of the invention are useful in high throughput screening for ligands which bind to G Protein-Coupled Receptors.01-26-2012
20120028275BIOMIMETIC MEMBRANE FOR CELL EXPANSION - The invention relates to a membrane which can be used for cultivating adherent or suspension cells, in particular adherent cells, wherein said membrane allows for the adhesion and proliferation of the cells due to modification of the membrane surface with a combination of at least one extracellular matrix protein, at least one extracellular matrix (proteo-) glycan, and at least one heparin-binding growth factor. The invention further relates to a method for preparing said modified or coated membrane which can be used for the cultivation of cells, in particular adherent cells, and to methods of using such membrane for the cultivation of cells, in particular adherent cells.02-02-2012
20130196346METHODS FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES (MDS) - The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.08-01-2013
20130196347METHOD AND DEVICE FOR ANALYSING MOLECULAR INTERACTIONS, AND USES THEREOF - The invention relates to a method for analysing an interaction between a first molecule and a second molecule bonded to a particle, including the following steps: contacting the first molecule with the second molecule bonded to the particle under conditions enabling the interaction thereof; applying a predetermined liquid flow to the particle bonded to the second molecule; observing a movement of the particle bonded to the second molecule caused by the applied flow; analysing the interaction according to the movement observed and the applied flow, the particle having a greater hydrodynamic resistance than the first and/or second molecule, and a mass Péclet number of greater than 1. The invention also relates to a device for analysing an interaction between a first molecule and at least one second molecule, as well as to the use of the method or of the device in screening a candidate molecule for developing a drug.08-01-2013
20130196348NEUROPEPTIDE Q AS MODULATOR OF GPCR GALR2 AND USES THEREOF - The invention relates to the identification of Neuropeptide Q as ligand of the GALR2 GPCR (G-protein coupled receptor). The invention encompasses the use of the interaction of GALR2 polypeptides and Neuropeptide Q polypeptides as the basis of screening assays for agents that modulate the activity of the GALR2 receptor. The invention also encompasses diagnostic assays based upon the GALR2/Neuropeptide Q polypeptide interaction, as well as kits for performing diagnostic and screening assays.08-01-2013
20130203078NOVEL ULTRASENSITIVE CELL BASED SENSORS AND USES THEREOF - The present invention relates to a novel cell based sensor useful for drug discovery that comprises a cell line with professional regulated exocytosis of secretory granules transfected with a protease as a reporter polypeptide stored in the regulated secretory granules of the cell line with professional regulated exocytosis and having either an endogenous or a heterologous molecule as a modulator of regulated secretory granules exocytosis, such said granule stored protease reporter having at least: a high resistance to conditions already present inside the granules such as low pH and proteolysis by other proteases; enzymatic activity after exocytosis; a highly specific cleavage sequence; a very low level of secretion under unstimulated or basal conditions; and a high signal to background activity in a media compatible with cell culture viability and granule exocytosis for a high throughput robust and sensitive detection.08-08-2013
20130203079ANTIBODIES FOR THE DETECTION OF INTEGRIN COMPLEXES IN FFPE MATERIAL - The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.08-08-2013
20120301899USE OF NOVEL MARKERS OF PLURIPOTENT STEM CELLS - The disclosure relates to novel markers of pluripotent stem cells and uses thereof, and particularly, though not exclusively, to antibody molecules based on fragments of mAb84 which bind to undifferentiated pluripotent stem cells via podocalyxin-like protein-1 (PODXL).11-29-2012
20120083003PARKIN SUBSTRATE AND ASSAY - The invention provides in vitro, ex vivo, and in vivo assays for Parkin activity, in which Parkin-mediated ubiquitination of a Sept4 protein is measured. The assays may be used to screen for agents that modulate Parkin protein ligase activity.04-05-2012
20120094310METHOD FOR DETERMINING BIOLOGICALLY ACTIVE HGF - The present invention relates to a for determining the presence, absence or amount of biologically active or inactive HGF in a sample, comprising the steps: bringing the sample in contact with a gel comprising a HGF binding component of the extracellular matrix or cell membrane, adding toluidine blue to the gel, correlating the colour of the gel and/or a liquid in contact with the gel with the presence, absence or amount of biologically active HGF in the sample. It also relates to a kit of parts comprising toluidine blue and a gel comprising at least one HGF-binding component of the extracellular matrix or cell membrane, such as a proteoaminoglycan or a glucosaminoglycan, and optionally buffers, vials and sampling instruments and to a gel comprising at least one HGF-binding component of the extracellular matrix or cell membrane, such as a proteoaminoglycan or a glucosaminoglycan, toluidine blue and HGF.04-19-2012
20130210032DEVICE, SYSTEM AND METHOD FOR DETECTING A SENSORY PERCEPTION - A device for detecting a sensory perception with regard to an analyte, having a sensor system and an organic receptor cell for detecting the sensory perception. The organic receptor cell is designed to assume a cellular state, which depends on the analyte in contact with the receptor cell. The sensor system is designed to determine the cellular state and to output it to the cellular state signal, which indicates the cellular state.08-15-2013
20130210033MARKER FOR AMYOTROPHIC LATERAL SCLEROSIS, AND USE THEREOF - An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like.08-15-2013
20090075341IL-21 ANTAGONISTS - Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.03-19-2009
20110195456Methods and compositions for the production of monoclonal antibodies - The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.08-11-2011
20090142807FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.06-04-2009
20120301923DIALYSIS FERMENTER-BIOREACTOR WITH DIALYSIS DEVICE - The present disclosure provides systems and methods of using a semipermeable membrane in a dialysis fermenter as a separation layer between a cell-containing liquid culture medium and a non-cell-containing dialysis medium. In some embodiments, the semipermeable membrane may have a molecular cut-off of 15 kDa to 50 kDa. The instant disclosure also provides a dialysis fermenter with compartments for cell-containing culture medium, non-cell-containing nutrient solution as well as an exchange unit having a semipermeable membrane, wherein mass transfer takes place between the culture medium and the dialysis medium by means of diffusion and/or ultrafiltration. Methods for culturing cells are also disclosed.11-29-2012
20080248531Preparation of fully human antibodies - The present invention provides a method of preparing fully human antibodies that recognize a pre-determined antigen without relying on human donors that have already been exposed to the antigen. To this end, lymphocytes from naive human donors are immunized in vitro with the antigen of interest, and cells that produce antibodies against the antigen are identified. Since the lymphocytes are immunized in vitro rather than in vivo, it is possible to control which antigen, or which part of the antigen, would be recognized by the antibody. A preferred antigen is gp120 of HIV, particularly the co-receptor binding region of gp120.10-09-2008
20110236931CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE - Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts.09-29-2011

Patent applications in class Animal cell

Patent applications in all subclasses Animal cell